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ABSTRACT 
 
The first known mention of the disease Rathamoolam (bleeding Hemorrhoids) 
is from 1700 BC Egyptian papyrus. The nature, etiology, types, clinical features and 
prognosis of Rathamoolam has mentioned in Yugimuni’s literature. The prevalence of 
Hemorrhoids ranges from 4.4% in the general population to 36.4% in general 
practice. Prevalence of Hemorrhoids in India according to recent survey is about 40 
million. It is now considered a major cause of morbidity and imposes burden on the 
society both economically and socially. Males and Females are affected with about 
equal frequency.  
Siddha recommended the Compatible diet and activities, cost effective easily 
available preparations and management of Rathamoolam (RM). Nelli Kudineer 
(NK) is one of the effective Siddha herbal preparations, mentioned in Gunapadam 
Moolikai. 40 patients including OP & IP, both genders were selected according to the 
criteria mentioned in the proforma and they were administered with trial drug Nelli 
Kudineer 100ml in the morning before food for one month.  
The pre clinical and clinical evaluations of Nelli Kudineer were carried out 
and results were showed its effectiveness for Rathamoolam. The panchabootham and 
its relations with gunam of Nelli Kudineer were proven for their activity in relieving 
the symptoms of Rathamoolam. 
The gradation of result was found to be good improvement in 73% cases, 
moderate improvement in 23% cases and mild improvement in 4% cases. 
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CHAPTER-1 
INTRODUCTION 
   Through the Spiritual, Intellectual and Systematic work of Siddhars, Siddha 
system developed. Everything in the universe is Iymboothamayam (Panchaboothas-
five elements).The Divine power guards the soul, mind and body. The body is 
constituted by the Panchabootha combinations and permutation is the supports for the 
soul are the 3 thathus namely Vatham, Pitham and Kapam. It attains 3 Gunas through 
Vaayu, Theyu and Appu. Ninety six thathuvas attained through an Embryo. It protects 
and supports the body and soul according to the ancient texts. 
Any vitiation from normal condition of Uyirthathu which deranges 
Udalthathu, any of 96 Thathuvams partially or totally and is manifested by 
characteristic symptoms and signs is called Noi (Diseases).Even though there are only 
3 dhosas, the diseases produced are many and can be grouped generally as Vali, 
Azhal, Iyam and Thontham. But Yugimuni revised this approach and classified 
disease based either on three humours (Kutram), Etiology, Clinical signs and 
symptoms for convenience and easy understanding of the disease. The widely 
accepted number of diseases according to Agasthiyar Ratna Churukka Naadi nool is 
about 4448. 
My selected topic is Rathamoolam (Bleeding Hemorrhoids) for the 
dissertation work. It comes under the heading of Eruvaaimulai noi/Moola noi 
(Anorectal diseases).Yugimuni classified Moolam into 21 types and Theran classified 
Moolam into 10 types. This topic Rathamoolam comes under Yugimuni classification. 
He described the clinical features of Rathamoolam are Pain in and around the 
Umbilicus and spurting of blood from rectum and anal canal which looks like splash 
in the pan, Weight loss, Anaemia, Easy fatigability, Oedema, Throbbing chest pain, 
Headache ,Drowsiness and Yellowish eye. Rathamoolam symptoms can be correlated 
in Modern medicine is Bleeding Hemorrhoids. 
Hemorrhoids (Greek:haima-blood,rhoo-flowing) are known as Moolam in 
Siddha and commonly known as Piles (Latin:pila-ball). Hemorrhoid is the saccular 
dilatation of Internal rectal venous plexus or Hemorrhoidal plexus, abnormal 
distension of Arterio-venous anastomosis, Prolapse of the cushions and surrounding 
connective tissue. Various factors responsible for the Hemorrhoids are Poor support to 
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veins, absence of valves in veins, compression of veins and direct transmission of the 
increased portal pressure at the Porto systemic circulation. To the above reason, 
development of Piles favoured by constipation, prolonged standing, excessive 
straining at stool and Portal hypertension. 
Hemorrhoids are classified into 2 types depending on their relation to anus. 
Internal Hemorrhoids lies inside the rectum and present with bright red rectal 
bleeding, when defecating. External hemorrhoids are under the skin around the anus, 
often result in pain and swelling in the anus. According to American society of colon 
and rectal surgeon is classified in grade I-IV of Hemorrhoid, Grade I is bleeding only, 
no prolapsed, Grade II: Prolapse that reduces spontaneously with or without bleeding, 
Grade III: Prolapse that require manual reduction, with or without bleeding, Grade IV: 
Irreducible prolapsed hemorrhoidal tissue.  
The prevalence of Hemorrhoids ranges from 4.4% in the general population to 
36.4% in general practice (Johanson et al 1990).The Prevalence of Hemorrhoids in 
India is about 40 million. It is now considered a major cause of morbidity and 
imposes burden on the society both economically and socially. Males and Females are 
affected with about equal frequency. 
Best treatment is to advice Compatible diet and activities. Provided treatment 
should be easy to administer, free of any significant complication, reduces the 
likelihood of surgery, cost effective and easily available. Many Siddha classical 
preparations offers wide range of herbal, animal, mineral and herbo -mineral 
combination to manage Moolam successfully with minimum or no adverse effect. 
Siddha provide the best alternative management as it act on the root cause of diseases. 
In Gunapadam Moolikai, Nelli (Phyllanthus emblica, Linn-Euphorbiaceae) is 
indicated for the management of Rathamoolam. So, Nelli Kudineer is known for their 
activity in relieving symptoms of Rathamoolam. Pre clinical and Clinical trials are 
recommended to evaluate the efficacy and safety of Nelli Kudineer in patients 
suffering from RM and various factors related to RM also described in this study. 
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CHAPTER-II 
AIM & OBJECTIVES 
AIM OF THE STUDY 
A  Prospective Open labelled Phase II Non Randomized clinical study of Nelli 
Kudineer for Rathamoolam (Bleeding Hemorrhoid). 
PRIMARY OBJECTIVE 
• To evaluate the clinical and therapeutic efficacy of Nelli Kudineer for 
Rathamoolam. 
SECONDARY OBJECTIVES 
• To analyze Phytochemicals in Nelli Kudineer. 
• To study the Pharmacological activities of the trial drug. 
• To determine the biochemical contents of trial drug. 
• To study anti microbial activity of the trial drug. 
• To analysis the safety profile of trial drug through Toxicity study. 
• To describe the panchbootha aspect of NK with its gunam for Rathamoolam. 
• To record the aggrevating factors and prevalence of Rathamoolam. 
• To perform the statistical analysis.   
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CHAPTER-III 
REVIEW OF LITERATURE 
III.1. NELLI DESCRIPTION 
TAXONOMY (WIKIPEDIA) 
Kindom :    Plantae 
Clade :       Angiosperms 
Clade:        Eudicots 
Clade:        Rosids 
Order:        Malpighiales 
Family:      Phyllathaceae 
Subfamily: Phyllanthoideae 
Genus:       Phyllanthus 
Species:     P.emblica 
SYNONYMS 
• Cicca emblica (L.) Kurz 
• Diasperus emblica (L.) Kuntze 
• Dichelactina nodicaulis Hance 
• Emblica arborea Raf. 
• Emblica officinalis Gaertn. 
• Phyllanthus glomeratus Roxb.  
• Phyllanthus mairei H.Lév. 
• Phyllanthus mimosifolius Salisb. 
• Phyllanthus taxifolius D.Don 
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                              Figure- III.1:Nelli parts 
           
                  LEAF                                                  ROOT 
             
                     FRUIT                                                                BARK 
                                                      
MACROSCOPIC APPEARENCE 
Phyllanthus emblica L, Emblica officinalis Gaertn, Euphorbiaceae family, a small 
or medium sized tree, found in mixed deciduous forests. It grows in Kurinchi and 
Marutham Thinai.Small tree with hairy reddish brown branchlets. Greenish grey or 
red bark.Leaves several, subsessile,distichous.Flowers greenish yellow,in axillary 
fascicles.Disc absent in male.Berry greenish yellow,globose and fleshy. The seeds are 
trigonous. 
Synonyms  
Tam:Amalakam,korankam,Mirutupala,Datri 
Eng:Emblic myrobalan 
Mal:Nellikka 
San:Amalaki,Amrithaphala,Dhathri 
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Chemical constituents 
                Fruits contain trigalloylglucose,terchebin,covilagin,ellagic acid,Phyllembic 
acid. Bark yields Leucodelphinidin,procyanidian,3-O-gallated prodelphinidin and 
tannin. The seed oil contain Vitamin C,carotene,Nicotinic acid,riboflavin,D-
glucose,D-fructose,myoinositol,embicol,mucic ,phyllembic acid,phyllembin and fatty 
acid etc.Root, bark, Leaf, Flower, Fruit, Seed are used in diseases of Pitham, Coryza, 
Constipation,Fainting,Polyuria,Anemia,Ascitis,Piles,Dropsy, Hypertension, asthma, 
Tuberculosis and it is a Rejuvenator(Yoganarasimhan S.N, Medicinal plants of India 
Vol 2,2000&The siddha Pharmacopoeia of India,2008) 
Described the Action: Fresh fruit is refrigerant, diuretic, laxative, carminative 
and stomachic. Dried fruit is sour and astringent. Flowers are cooling and 
aperint.Bark is astringent (Purushotam kaushik &Anil kumar Dhiman, Medicinal 
plants and raw     drugs of India, 1999) 
GUNAPADAM-MOOLIGAI         
Variousnames:Aamalakam,Aalakam,Aambal,Aamarikam,thaaththaari,Thaaththiri,Kor
ankam,miruthupala,Meethunthu. 
Parts used: Leaf, Flower, Bark, Root, fruit, seed. 
PROPERTIES AND ACTIONS OF NELLI 
                  Table-III.1: Properties of Nelli 
Taste(suvai) Sour,Astringent,Sweet 
Potency(Thanmai) Cold 
Post absorptive taste(Pirivu) Sweet 
                  Table-III.2: Actions of Nelli 
Parts Action 
Leaf, bark,dried fruit Astringent 
Flower Refrigerant,Laxative 
Fruit Refrigerant,Diuretic,Laxative 
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Pothu gunam 
        If nellikkai is taken in day time, following disease will cure.It is illustrated in 
Theraiyar gunavakadam and Pathartha guna chinthaamani 
“ 	 
	  
 	 - 
 	  ! "" 
#	 $%”. 
The following disease will cure, 
• Pitha noi 
• Iya noi 
• Peenisam 
• Vaayneer 
• Vaanthi 
• Mayakkam 
According to Theraiyar gunavakadam and Patharthaguna chinthaamani, 
            “#&' 	 &  ()'* 
+" , "$--+	 
. / 0  1+2" 
34 "	 "*35.” 
Above poem revealed that nellikkai will cure 
• Pitha diseases 
• Vatha diseases 
• Kapha diseases 
• Diabetes 
Root 
      According to Agasthiyar Gunavakadam and Patharthaguna chinthaamani, 
Root of nelli is used to cure following diseases. 
• Vaanthi 
• Agusea 
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• Normalizes Thirithodam 
• Suram 
• Sanni 
“	 1"-/5	   6 57 
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 According to Theraiyar Yamaka venba 
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Nellimulli 
According to Theraiyar Gunavakadam and Patharthaguna chinthaamani, therapeutic 
uses of Nellimulli described 
“A 7/1 /= ( B%"C 
- 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• Eye diseases 
• Thirst 
• Blood loss 
• Thathunattom 
• Mega noi 
According to Theraiyar gunavakadam and Patharthaguna chinthaamani, 
“## E)$ #& &/	 
1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	 F%”. 
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Nelli will cure following diseases 
• It will give taste totongue 
• Neutralizes the Pitham 
• Coolinf to eye 
• Pitha vaanthi 
• Meganoi 
In Patharthaguna chinthaamani, 
E -2C ./- ! 
C ()#-I 4-C 
" EI5& %/- 6	 
  	
 . 
Plants that cure piles are 
• Marul 
• Saaradai 
• Karunai 
• Vachiravalli 
• Kaattukarunai 
• Pulinaralai 
• Karaa karunai 
• Merugu 
• Vellaruku 
• Venchithiramoolam 
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III.2. JOURNAL PUBLICATIONS OF NELLI 
Phytochemical and Acute toxicity study of Emblica 
Pandey Govind and Pandey (2011) have done the work of Phytochemical and 
Acute toxicity study of Emblica officinalis, at the end of the study he found 250,500 
and 1000 mg/BW of F.Albino rats,which showed LD50 for more than 1000mg/kg and 
further determined Hydro alcoholic extract of Emblica fruit showed the presence of 
Alkaloids,Glycosides,Tannins and Steroids. 
Antibiotic activity of Emblica 
Shubhi mehrotra et al.(2010)had determined the Antibiotic activity of Emblica 
,it is effective against the three target pathogens,viz S.aureus,V.cholerae, and 
P.aeruginosa,Zone of Inhibition(ZIC) is 0.025,0.025and0.025(ug/ul)respectively 
Anti cancer activity of Nelli 
Gamkitidechakul N et al. (2010) have observed that the aquous extract of 
Amla containing Tannins (43%).Uronic acid (11%), and Gallic acid(21%) was 
effective in delaying and reducing DMBA induced and12-0-tetradecanoylphorbol-13-
acetate-promoted skin carcinogenesis in mice. 
Role in humoral immune response 
Qari Muhammed Kaleem et al.(2014) studied on Emblica derived Tannins for 
their Immunostimulatory and protective activities againt Coccidiosis in Industrial 
Broiler Chicken.The study revealed that Tannins has vital role in humoral immune 
response in sheep red blood cells by haemagglutination assay(P ≤ 0.005) 
Antiatherogenic, anticoagulant, hypolipidmic, antihypertensive, antioxidant, 
antiplatelet and vasodialatory effects 
Fataneh Hashem et al.(2018) article reviewed the Emblica officinalis’s(EO) 
potential for prevention and therapy of cardiovascular diseases. PubMed, 
ScienceDirect, Scopus, Proquest, Ebsco, Google, Ovid and Cochrane databases were 
searched from 1966 to 2017.Nineteen articles concerning the cardiovascular 
pharmacological effects of EO were included in this review. The plant has shown 
Antiatherogenic, anticoagulant, hypolipidmic, antihypertensive, antioxidant, 
antiplatelet and vasodialatory effects as well as lipid deposition inhibitory properties. 
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Plants having Antihemorrhoidal properties 
         Table-III.3: Plants having AntiHemorrhoidal properties Bharat Gami (2011) 
Plant Name Chemical 
constituents 
Family Parts used 
Centella asiaticaL Triterpen,saponin Apiaceae Whole plant 
Aesculus 
hippocastanum L 
Triterpen,saponin Hippocatanaceae Seeds 
Ruscus aculeatus  Saponin,glycoside, 
ruscogenin 
Liliaceae Rhizomes 
Hamamelis 
virginianaL 
Tannins,Volatile oil Hamamelidaceae Bark 
Gingko bilobaL Bioflavanoid,Hesper
idin 
Ginkgoaceae Leaves 
Rosa canina Vitamin C Rosaceae Fruits 
Silybum marianum Flavanolignans,silyd
isnin,silychristine, 
silymarin 
Asteraceae Fruits,seeds 
Commiphora mukul Diterpenoids Burseraceae Gum resin 
Azadirachta indica Sulphur containing 
bitter principle 
Meliaceae Seeds 
 
Emblica officinalis Vitamin C,Tannin Euphorbiaceae Fruits 
Terminalia chebula Tannin Combretaceae Fruits 
Cassia fistula Tannin Caesalpinaceae Pod 
Calendula 
officinalisL 
Salicylic acid Asteraceae Essential oil 
Mimosa pudicaL ------ Fabaceae Whole plant 
Vitex negundo Tannin Verbenaceae Whole plant 
Eclipta alba Alkaloids Asteraceae Whole plant 
Plantago ovate Mucilage Plantaginaceae Seeds 
Collinsonia 
canedensis L 
Flavanoids,saponins Lamiaceae -------- 
Matricariarecutita  -------- Asteraceae Dried flower 
Lupinus albus VitaminC,Vitamin E Fabaceae -------- 
Vateria indica Bitter resin Dipterocarpaceae --------- 
Mentha piperita Pungent oil Labiatae Leaves 
Aloe vera Anthraquinone 
glycosides 
Liliaceae Dried juice 
of leaves 
Cupressus 
sempervirens 
------- Cupressaceae Twigs of 
young 
branches 
Pelargonium 
graveolens 
--------- Geraniaceae Leaves and 
stems 
Juniperus communis 
Linn 
-------- Cupressaceae Essential oil 
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Importance of Flavanoid in Hemorrhoid 
Alonso et al. (2006) carried out the study regarding the flavonoid sand 
symptomatic Hemorrhoids. They reported, reduction in the risk of bleeding,persistent 
pain,Itching and reoccurrence. Recommended that more in-depth study with effective 
methodological quality needed for the apparent beneficial effects of flavonoid for the 
treatment of hemorrhoids. 
Anti inflammatory and Dyslipidemic effect of Nelli 
Antony B et al (2008) carried out a pilot clinical study to evaluate the effect of 
EO extract on markers of systemic inflammation and dyslipidemia. Purified, 
standardized, dried extract of amla containing about 35% galloellagi tannins along 
with other hydrolysable tannins were used for this trial . Their earlier studies on 
rabbits showed significant reduction in total cholesterol and triglycerides as well as 
increase in HDL. This study extends these results to human volunteers. Two doses of 
the extract were evaluated 500 mg and 1000 mg per day for 6 months. Blood samples 
were collected at the 3rd and 6th months showed reduction in total and LDL 
cholesterols and enhancement of beneficial HDL cholesterol. In addition, blood CRP 
levels, a marker for inflammation, were also significantly reduced. 
Antioxidant action of Emblica 
Renuka Chaphalkar et al. (2017) conducted a study on Antioxidants of 
Phyllanthus emblica bark extract (PEE) provide hepato protection against Ethanol 
induced Hepatic damage. They investigated the protective effect of the hydroalcoholic 
extract of Phyllanthus emblica bark (PEE) in ethanol-induced hepatotoxicity model in 
rats. Total phenolic, flavonoid, and tannin content and in vitro antioxidant activities 
were determined by using H2O2 scavenging and ABTS decolorization assays. This 
result showed that PEE was rich in total phenols (99.523 ± 1.91 mg GAE/g), total 
flavonoids (389.33 ± 1.25 mg quercetin hydrate/g), and total tannins (310 ± 0.21 mg 
catechin/g), which clearly support its strong antioxidant potential. HPTLC-based 
quantitative analysis revealed the presence of the potent antioxidants gallic acid 
(25.05 mg/g) and ellagic acid (13.31 mg/g). Moreover, one-month PEE treatment (500 
and 1000 mg/kg, p.o.) followed by 30-day 70% ethanol (10 mL/kg) administration 
showed hepatoprotection as evidenced by significant restoration of ALT (p < 0.01), 
AST (p < 0.001), ALP (p < 0.05), and ATP (p < 0.001) and further confirmed by liver 
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histopathology. PEE-mediated hepatoprotection could be due to its free radical 
scavenging and antioxidant activity that may be ascribed to its antioxidant 
components, namely, ellagic acid and gallic acid. 
Action of Nelli on Vascular smooth muscle 
Junxuan Zhou et a.l(2018) their study illustrated that Emblic leaf flower fruits 
ameliorate vascular smooth muscle cell dysfunction in hyperglycemia, an underlying 
mechanism involved in Ellagitannin metabolite Urolithin A. In this study, 
acetylcholine-induced endothelium-independent relaxation in aortas was facilitated 
upon emblic leaf flower fruit consumption in the single dose streptozotocin-induced 
hyperglycemic rats. Emblic leaf flower fruit consumption also suppressed the 
phosphorylation of Akt (Thr308) in the hyperglycemic aortas. More importantly, 
urolithin A (UroA) and its derived phase II metabolites were identified as the 
metabolites upon emblic leaf flower fruit consumption by HPLC-ESI-Q-TOF-MS. 
Moreover, UroA reduced the protein expressions of phosphor-Akt (Thr308) and β-
catenin in a high glucose-induced A7r5 vascular smooth muscle cell proliferation 
model. Furthermore, accumulation of β-catenin protein and activation of Wnt 
signaling in LiCl-triggered A7r5 cells were also ameliorated by UroA treatment. In 
conclusion, their data demonstrated that emblic leaf flower fruit consumption 
facilitates the vascular function in hyperglycemic rats by regulating Akt/β-catenin 
signaling, and the effects are potentially mediated by the ellagitannin metabolite 
urolithin A. 
III.3. SIDDHA LITERATURE REVIEW OF RATHAMOOLAM 
Rathamoolam is one among the twenty one types of Moolanoikal, described 
by Yugimuni. Moolam in Siddha means the area of Moolaatharam or the Root. A 
disease associated with Moolathara region is Moolarogam or Anorectal diseases.They 
are also called Adimulai noi, Arippu noi , Eruvaimulai noi and Mulai noikal. 
IMPORTANCE OF MOOLAATHARAM 
According to Chattamuni jnanam Moolathara area has been given 
importance in Siddha systems as it is the energy center of the body, the Kundalini. 
The Chattaimuni jnanam verses tell about the importance of moolathara among six 
aathaarams. So, according to chatta muni, moolaatharam is a vital role of the disease. 
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UDAL KOORUKAL 
 The total length of the GIT is thirty two muzham and the spindle like shape of the 
intestine occurring during peristalsis and the taeniae in the large intestine are known 
as ‘Arai’. These are 1008 in number. They look like kumizhi, ie.bubble like masses in 
a long tunnel. These structures are controlled by the six chakras and the guru naadi. In 
the moolathara area the large intestine is to function normally in association with 
other systems in the region particularly related to vaayus vairavan and sanguni. 
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 Nine narambukal are held responsible for deglutition, digestion, absorption and 
defaecation. Out of these, one narambu is responsible for the purpose of visarkkam. 
The narambu divides into four branches in the moolatharam and supplies large 
intestine, urinary bladder, sukkilasayam, kaariral and suvaasapai. This narambu in 
association with other thathuvams such as ten vayus carryout the act of visarkkam. 
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UDAL THATHUVAM 
                        Moolathara is situated in the akkini manadalam and vatha area is 
below the navel. Predominent bhoothams are Vaayu Theyu and Akaayam. Theyu is 
for akkini mandalam and the rest for vatha area. This structure makes this area having 
more kinetic (due to vaayu) and thermal energies (due to theyu) to facilitate the 
normal act of micturition, defaecation and parturition. To control defaecation and to 
carry out (kanmavidayam) visarkkam, the bootham involved is neer. The 
kanmenthiriyam involved here is Eruvai. 
 Vaayu and Akayam together constitute Vatham.Vatham in the body manifests 
as 10 types. The types directly concerned with moolathara area are Abanan,Pranan 
and Devathathan. Abanan is a vaayu having theyu predominance in its structure. In 
relation to malasayam it effectively expels faeces. Prana vaayu takes its course via 
moolathara area and it takes saaram from here and disperses to all tissues of the body 
in addition to its main function of respiration. Devathathan relates the mental states of 
the human body due to Rathamoolam. It normally resides in the rectum and is 
responsible for anxiety, anger, quarelling and laziness. Theyu in malaasayam manifest 
as moolakkini. Moolakkini is a kind of akkini in the body gives the required 
metabolic thermal energy to malasayam to facilitate the normal act of visarkkam. 
Neer bootham carries out the act of visarkkam in the kanmenthiriyam Eruvai. The 
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action of neer bootham is very essential, but uncontrolled action by vaayu, akayam 
and theyu leads to decrease in Neer bootham and  may result in pathology. 
According to Theraiyar narambu soothiram 150, In the ten naadis, the 
malasaya naadi is Guku. Suzhumunai naadi also has its base in the moolatharam. 
These naadis carryout coherent action of other systems in normal act of digestion, 
absorption and defecation.  
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TYPES OF MOOLAM (NOI ENN) 
Yugi 
vaidhya 
chinthamani 
(21 types) 
Cegaraasasekaram 
(20 types) 
Theraiyar 
(10 types) 
Agathiyar 
paripooranam 
(9 types) 
Anubava 
vaidhya 
ragasiyam 
(6 types) 
Jeeva 
ratchamirthan 
(4 types) 
Neer 
Chendu  
Mulai  
Siru  
Varal 
Ratha 
Seezh  
Aazhi  
Thamaraka  
Vali  
Azhal  
Iya  
Thontha  
Vinai  
Mega  
Pavuthira  
Kiranthi  
Kutha  
Pura  
Churukku  
Chavvu  
Vatha  
Pitha  
Kapa  
Vatha Pitha  
Pitha Vatha  
Pitha Kapa  
Setha Vatha  
Sada Vatha  
Kapa Sala  
Ul  
Ulaththu  
Athisara sura  
Thosha thontha  
Vatha raththa  
Vatha Kerppa  
Pitha Vatha Thontha 
Pitha Kapa Thontha  
Kanda  
Ratha  
Serpa  
Seezh  
Punn  
Thee  
Neer  
Mulai  
Sathai  
Kaduppu  
Veluppu  
Kaatru  
Perumulai 
 
Ratha  
Seezh  
Mulai  
Moola paandu 
Vali  
Azhal  
Iya  
Ul  
Pura  
Vatha  
Pitha  
Kapa  
Thontha  
Thirithoda  
Ratha. 
 
Sagasa 
(hereditary) 
Uththarasa 
(natural) 
Shutka 
(shrinking) 
Aarthira 
(discharge) 
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Yugi vaidhya chinthamani -800(Stanza 639-669) 
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 The  above literature explained,diseases are classified  as 4448 in numbers. Moola 
rogam is of nine types 
ETIOLOGY (NOI VARUM VAZHI) 
Primary cause of Moolanoi 
Accoding to Theriyar concept, 
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Rathamoolam Initially from derangement of Vatham and Pitham.Initially in 
any pathological state the affected Thathuvams are the Panchabootham.The various 
etiological factors deranges the normal structure of Vayu, Akayam and Thee bootham 
in the Moolatharam.If this state is allowed to persist then the bootham responsible to 
carryout kanmavidayam visarkkam, Neer get deranged in the very long run.Since 
Vayu and Akayam constitute Vatham and Thee constitute Pitham,immediately these 
two humours derange. 
Vatham in the body manifests as 10 vayus,among them those having 
connection with the Anal canal is Abanan,Pranan and Devathathan get 
deranged.Simultaneously with vayus,Naadi is having connection with Moolatharam 
i.e.Guku and Suzhumunai along with other Thathuvams produce systemic 
manifestations. Pitham in the body manifests as 5types viz Anal, Ranjakam, 
Prasakam, Alosakam and Saathakam. All these are affected in Rathamoolam. Kapam 
deranges very lately, if left untreated and will cause sobai noi. 
According to Yugimuni, 
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 The above poem was mentioned the following characteristic intrinsic causes 
of Incompatible diet and acts include, 
• Exposure to excessive cold 
• Exposure to excessive heat 
• Excessive heat in the body due to Kiranthi noigal (STD) 
• Indulging excessively in sexual activities 
• Excess intake of Pungent and Salt diet. 
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The following karmic activites can causes for the disease, including 
• Chiding the elders 
• Doing harm to others 
• Indulging in rape 
• Thinking of doing harm in the mind but saying sweet words in front 
• Living a luxurious life when others are in hunger 
• Quarrelling with others 
Psychological cause described is, 
• Angry 
• Anxiety and Depression 
Other Causes  
• Maintaining wrong Yogic postures 
• Predispose to vitiated Vatham, Pitham and Moolakkini leading to Moola noi. 
According to Subramani varama avathinithanam-500, was described the etiology 
due to deranged varma nilai. 
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Agasthiyar gunavakada thirattu, Pathinen siddhar aruli chaitha naadi, 
Athamaratchamiritham, Agasthiyar-12000 described the etiology of Rathamoolam, 
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(Agathiyar 2000) 
• Excess intake of Non-veg foods 
• Excess intake of fatty substances 
• Hunting 
• Intake of Kummattikkai 
• Intake Pig meat 
• Sleep in day time 
• Supression of hunger 
PATHOGENISIS 
Noi naadal Noi muthal naadal thirattu I describes the Pathology of Moolam.It 
basically result from derangement of Vatham and Pitham. Initially in any pathologic 
state the affected thathuvams are the Panchabootham, The various etiological factors 
of Ratha moolam deranges the normal structure of Vaayu,akayam and Thee bootham 
in moolatharam, if this state is allowed to persist then the bootham responsible to 
carryout the kanmenthiriyam visarkkam,neer gets deranged in the very long run,since 
vaayu and akayam constitute Vatham and Thee constitute Pitham,immediately these 
two humours deranged. Vatham in the body manifests as 10 vaayus. Among them 
those having connection with the anal canal is Abanan, Piranan and Devathathan get 
deranged. At the same time Naadis having connections with the moolatharam is Guku 
and suzhumunai along with other thatuvams produce systemic manifestations. Pitham 
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in the body manifests as Five types viz Anal, Ranjakam, Prasakam, Alosakam and 
Saathakam. All these are affected in Rathamoolam. Kapam deranges very late stage if 
the patient is left untreated for longer duration and causes sobai. 
In Rathamollam primarily affected vaayus are Abanan, Pranan and 
Devathathan. These deranged vaayus affect seven thathus and Malams. Due to this 
symptoms produced in rathamoolam are Pain in and around umbilicus, splashing of 
blood during defaecation, weakness, and headache. Pain in umbilicus and Splashing 
of blood during daefaecation are symptoms of affected abanan. Feeling of weekness 
in the limbs, headache is the characteristic features of pranan involvement. 
Devathathan produces anxiety due to loss of blood. 
As molatharam is in the akkini mandalam, any pathological condition here can 
harm moolakkini and eventually Pitham. In Rathamoolam, all the Pithams are 
affected except Analpitham initiallay. Later when Veluppu noi ensues, it gets also 
affected leading to reduced appetite. The primarily deranged Pithams are Ranjaka, 
Prasaka, Aalosaka, Saathaka pitham. Symptoms are produced when these deranged 
pithams affect the seven thathus and malam. These symptoms include Pale skin, 
Veluppu noi, yellow colour eye,giddiness and emaciation. Veluppu is due to 
derangement of ranjakam. Paleness of skin is due to derangement of prasakam, yellow 
colour eye is due to derangement of Alosakam, giddiness and emaciation are due to 
derangement of sathakam. 
Kapam has neer and Prithvi boothams.It is responsible for coordination and 
defense mechanism of the body. Initially in Rathamoolam, kapam is not deranged but 
in untreated cases all the five types of kapam are affected. This causes pathologic 
changes in the thathus leading to sobai noi.When Vatham, Pitham and kapam are 
deranged, they affect udal thathus(saram,senneer,oon,kozhuppu,enbu,moolai,sukilam 
or suronitham) and udalthee. It will afeect three malams and intern produce various 
symptoms according to severity and site of ailment. 
In Rathamoolam primarily affected thathus are saram, senneer and oon.The 
symptoms of Rathamoolam are typically due to vitiation of these thathus. In udalthee, 
moolakkini is affected.Moolakkini along with abaanan causes bleeding per anus 
which is the main symptoms. Due to malam derangement constipation, Irritation 
around anus results. 
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Thirumolar karukkidai vaidhyam-600 mentioned the Pathology of RM 
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Describes the pathology of Rathamoolam in above poem is. The Suppression 
of appetite and defaecation leads to derangement of vayu.This vayu enters kundalini 
area.Here the vayu combines with theyu and causes formation of 
moolamulaikal.When excess vayu exerts pressure on them,they bleed on straining 
ie,while defaecation 
CLINICAL FEATURS (KURI GUNANKAL) 
 According to the Yugi munivar in chinthamani, poem no 650 is, 
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• Pain around umbilicus 
• Bleeding per anus 
• Emaciation of body 
• Pallor 
• Weakness of extrimities 
• Sogai 
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• Chest pain 
• Headache 
• Mayakkam 
• Yellowish eye. 
According to Agathiyar gunavakadam, mentioned the clinical features,prognosis 
and symptomatic treatment in Rakthamoola noi.  
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According to the above poem the predominant symptoms of this diseases 
includes protrusion of tortured pile mass followed by anal bleeding, fatigue, and 
headache. In this condition nutritious diet which is laxative should be given to the 
patient. When the patients developed the symptoms of dehydration like pallor in the 
lips, feeble pulse peechu should given with the decoction prepared by Masikkai which 
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has styptic action will arrest the bleeding. Clinical features are presence of pile mass, 
Swelling of pile mass, bleeding per rectum. 
According to Sekharasa Kesaram clinical features are described by below verses 
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From Thirumoolar Karukkidai Vaidhyam-600 clinical features described as 
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The above poem reveled the clinical features of Moolam.i.e. Burning 
sensation in anus, derangement of Vinthu, Iraichal(gurgling)and Diarrhoea. 
In Siddha maruthuvam pothu, Murkuri gunam (Premonitory symptoms) described  
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Premonitory symptoms are 
• Constipation 
• Protrusion of pilemass 
• Burning sensation in anus 
• Derangement of Vinthu 
• Iraichal 
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According to Theraiyar sekarappa, Pothukuri gunangal (Clinical features)as 
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The Pothu kuri gunankal(clinical features)as Faeces become hard and white in 
color and their passage in the anus gets blocked as if there is bud of lotus.Then the 
pile mass protrudes like a lotus flower with the active play of vayu.Bleeding per anus 
occurs like honey drops from the lotus flower.Malaise, Physical and mental fatigue 
also will develop.This disease is an irritating and the affected person looks like an 
afraid serpent due to heavy thunder. 
In the literature Gunavakadam, Clinical features described are 
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• Pain around the umbilicus 
• Bleeding from rectum 
• Prolapsed rectal mass 
• Secondary anemia due to bleeding 
Aaviyalikkum amuthamurai churukkam: 
The above book was mentioned the clinical features of Hemorrhoids 
• Loss of appetite 
• Lower abdominal discomfort 
• Constipation 
• Pain around umbilicus 
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• Bleeding per anus 
• Drowsiness 
• Anaemia 
• Breathlessness 
Athmaratchamirtham entra vaidhya saara sangirakam 
The above book was described the following clinical features are, 
• Consuming food with bitter and sour tastes 
• Warm body 
• Loss of appetite 
• Lower abdominal discomfort 
• Constipation 
• Pain around umbilicus 
• Bleeding per rectum 
• Protrusion of pile mass 
• Irritation and burning sensation in the anus 
• Anaemia 
Veerama munivar aruli cheytha nasakanda venba 
The clinical features are, 
• Pain in the Umblicus 
• Spurting out of blood during defaecation 
• Emaciation 
• Pallor 
• Weakness in limbs 
• Sobai 
• Chest pain 
• Headache 
• Giddiness 
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PROGNOSIS (SAATHIYAM / ASAATHIYAM) 
Saathiya Moolanoikal (Curable types) 
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1. Neer moolam 
2. Mulai moolam 
3. Varal moolam 
4. Rathamoolam 
5. Vatha moolam 
6. Pitha moolam 
7. Mega moolam 
8. Pavuthira moolam 
9. Kiranthi moolam 
10. Pura moolam 
11. Churukku moolam 
12. Chavvu moolam 
Asaathiya Moolanoikal (Incurable types) 
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1. Chendu moolam 
2. Sitru moolam 
3. Seezh moolam 
4. Aazhi moolam 
5. Thamaraka moolam 
6. Vinai moolam 
7. Silethuma moolam 
8. Kutha moola 
9. Thontha moolam. 
 
NAADI NADAI  IN RATHAMOOLAM 
According to Theraiyar, Primary Naadi in Rathamoolam is Pitham 
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Vallathi naadi 
Pithathil vatham is the diagnostic naadi for moolanoikal 
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Sathaka naadi 
Describes the pathological naadi for Moola noi 
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Gunavakada noin saaram 
Vatham,Pitham and Kapam are decreased  from their normal state in Moolam 
 “6 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	”. 
DIAGNOSIS (PINIYARAI MURAI) 
Diagnosis by Porial Arithal, Pulanal therthal, Vinathal, which include detailed 
history of patient and Envagaithervukal, which include Naadi,Sparisam,Naa, Niram, 
Mozhi, Vizhi, Malam and Moothiram 
DIFFERENTIAL DIAGNOSIS (NOI KANIPPU VIVAATHAM) 
• Chendu moolam 
• Muli moolam 
• Varal moolam 
• Aazhi moolam 
• Thamaraka moolam 
• Azhal moolam 
• Churukku moolam 
• Rathasoolai moolam 
• Vazhi kuruthi azhal noi 
COMPLICATIONS 
When moolakhni is highly vitiated it will cause worst complications according 
to Thiruvalluva Nayanar Navarathna Chinthamani-800. The main complications are 
veluppu noi due to deranged azhal and sobai due to deranged iyam which mentioned 
in Yugi Vaidhya Chinthamani. Moolam accompanied by edema of extremities, 
abdomen, face, anal region and umbilicus results in death. If moolam come as a 
complication of Magotharam and preliminary disease of paandu, kaamalai, gunmam 
30 
 
and kazhichal will cause more complications. If moolam accompanied by 
Kudhakeelam they felt intolerable pain. 
LINE OF TREATMENT 
• Administration of internal medicine to normalize the Vatham&Pitham and to 
reduce the vitiated moolakkini. And medicines to stop bleeding, to reduce 
inflammation and to relive constipation. 
• Pathiyam, i.e. diet to normalize the vitiated vatha pitha thontham and to 
maintain the effectiveness of drug. 
• Yoga therapy and pranayama therapy to normalize the bowel habit and 
mukkutram. 
PATHIYAM FOR RATHAMOOLAM (DIET) 
Anubava vaidhya deva ragasiyam prescribed the following diet regimen 
• Cows buttermilk  
• Cows butter  
• Cows ghee 
• Pepper  
• Asafoetida 
• Rock salts 
• Tender mango 
• Caster oil 
• Fresh green such as araikeerai, siru keerai, thuthulai keerai, venthaya keerai, 
manathakkali keerai, mullanki keerai. 
APATHIYAM (DIET RESTRICTION) 
• Fish 
• Meat 
• Black gram 
• Ragi 
• Rye  
• Bitter guard 
• Maize 
• Oil cake of eluppai 
• Hot foods and drinks 
• Motchi 
• Brinjal 
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III.4. MODERN ASPECT OF RATHAMOOLAM 
DEFINITION 
Hemorrhoids are dilated veins occurring in relation to the anus.  
TYPES 
1. Internal hemorrhoids: saccular dilatations of internal rectal venous plexus, 
occur above the pectinate line. Bleed profusely during straining at stool. 
2. External piles: it occur below the pectinate line    
ETIOLOGY 
1. Poor support to veins the surrounding loose connective tissue 
2. Absence of valves in superior rectal and portal vein 
3. Compression of the veins at the sites where they pierce the muscular coat of 
the rectum 
4. Direct transmission of the increased portal pressure at the portosystemic 
communications 
For the above reason development of hemorrhoid is favored by 
• constipation  
• prolonged standing  
• excessive straining at stool  
• portal hyper tension 
PATHOPHYSIOLOGY 
 The most commonly accepted hypothesis is sliding of the anal canal lining 
when the supporting tissues of the anal cushions become non-functional and the anal 
cushions bulge downwards.The sites of the three major anal cushions are: right 
anterior, right posterior and left lateral. Histological evaluation of these anal cushions 
reveals a variety of changes. These include vascular dilatation, vascular thrombosis, 
degeneration of supportive tissues of the mucosa and rupture of the anal submucosal 
muscle. These changes are superimposed with inflammation. 
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CLINICAL EVALUATION 
 The commonest presenting feature is rectal bleeding. The bleeding is bright red in 
color in the form of spurts. It usually follows the passage of stools. As a result, the 
stools are covered with fresh blood. The bleeding at times, may be so severe that the 
patient may develop anemia which may, at times, be the presenting feature of 
hemorrhoidal disease in a select few patients. Constipation is a common 
accompaniment of this condition. Long term straining while passing stools is the 
commonest symptom. Patients spend a significant amount of time in an attempt to 
have a satisfying bowel evacuation. Pruritis ani may also be a symptom in cases of 
prolapsed piles. 
INVESTIGATION 
  Per digital and proctoscopic examination is the first step in the diagnostic workup. 
Digital examination will help assessing a rectal growth as well as confirming the 
presence of fresh blood in the rectum. A proper proctoscopic examination will help in 
confirming the diagnosis. The grade of piles can be determined by a good 
proctoscopic examination. It is also a safe procedure to subject all patients suffering 
with hemorrhoids to undergo colonoscopic evaluation in order to rule out colorectal 
malignancy. 
COMPLICATIONS 
• Profuse haemorrhage 
• Strangulation 
• Thrombosis 
• Ulceration 
• Gangrene 
• Fibrosis 
• Suppuration 
• Pylophlebitis  
DIFFERENTIAL DIAGNOSIS 
• Fissure in ano 
• Ano-rectal abscess 
• Perianal haematoma 
• Prolapse of rectum 
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• Fistula in ano 
• Portal hypertension 
• Carcinoma of the rectum 
TREATMENT 
• Symptomatic  
• Injection of sclerosant 
• Banding  
• Photocoagulation 
• Hemorrhoidectamy 
III.5. JOURNAL PUBLICATIONS OF HEMORRHOID 
Review of Hemorrhoid 
Zhifei sun and John Migaly(2016)published the Review of Hemorrhoid: 
Presentation and Management .Symptomatic hemorrhoid disease is one of the most 
prevalent ailments associated with significant impact on quality of life. Management 
options for hemorrhoid disease are diverse, ranging from conservative measures to a 
variety of office and operating-room procedures. In this review, the authors discussed 
the anatomy, pathophysiology, clinical presentation, and management of hemorrhoid 
disease. Anatomy and Pathophysiology:Hemorrhoids are clusters of vascular tissues, 
smooth muscles, and connective tissues that lie along the anal canal in three 
columns—left lateral, right anterior, and right posterior positions. Because some do 
not contain muscular walls, these clusters may be considered sinusoids instead of 
arteries or veins. Hemorrhoids are present universally in healthy individuals as 
cushions surrounding the anastomoses between the superior rectal artery and the 
superior, middle, and inferior rectal veins. Nonetheless, the term “hemorrhoid” is 
commonly invoked to characterize the pathologic process of symptomatic hemorrhoid 
disease instead of the normal anatomic structure. 
Raakhi Mehra et al. (2011) study was carried out using a combination of 
apamarga kshara Basti and Triphalaguggulu.The results of the clinical assessment of 
the indigenous formulation on patient with Bleeding hemorrhoids were reported in 
this paper. The following disease criteria were used in this study. 
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1. Bleeding per anus 
2. Pain 
3. Constipation 
4. Protrusion of pile mass 
5. Mucus discharge 
6. Itching around anus 
7. Anemia 
Varut lohsiriwa(2012) published the journal of Hemorrhoid from basic 
pathophysiology to clinical management,this review discussed the pathophysiology, 
epidemiology, risk factors, classification, clinical evaluation, and current non-
operative and operative treatment of hemorrhoids. Hemorrhoids are defined as the 
symptomatic enlargement and distal displacement of the normal anal cushions. The 
most common symptom of hemorrhoids is rectal bleeding associated with bowel 
movement. The abnormal dilatation and distortion of the vascular channel, together 
with destructive changes in the supporting connective tissue within the anal cushion, 
is a paramount finding of hemorrhoids. It appears that the dysregulation of the 
vascular tone and vascular hyperplasia might play an important role in hemorrhoidal 
development, and could be a potential target for medical treatment. In most instances, 
hemorrhoids are treated conservatively, using many methods such as lifestyle 
modification, fiber supplement, suppository-delivered anti-inflammatory drugs, and 
administration of venotonic drugs. Non-operative approaches include sclerotherapy 
and, preferably, rubber band ligation. An operation is indicated when non-operative 
approaches have failed or complications have occurred. Several surgical approaches 
for treating hemorrhoids have been introduced including hemorrhoidectomy and 
stapled hemorrhoidopexy, but postoperative pain is invariable. Some of the surgical 
treatments potentially cause appreciable morbidity such as anal stricture and 
incontinence. The applications and outcomes of each treatment are thoroughly 
discussed. 
Mahmoud sakre and Khaled saed(2014)published the journal of Recent 
advances in the management of hemorrhoids. They described that hemorrhoids are 
considered one of the most common anorectal diseases with a prevalence of 4.4% up 
to 36.4% of the general population, and a peak incidence between 45 and 65 years. 
Hemorrhoidal disease presents with a prolapsed lump, painless bleeding, discomfort, 
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discharge, hygiene problems, soiling, and pruritus. Sliding anal canal lining theory is 
the most accepted theory as a cause of hemorrhoidal disease; however, it is also 
associated with hyper-vascularity, and, recently, with several enzymes or mediators 
involved in the disintegration of the tissues supporting the anal cushions, such as 
matrix metalloproteinase. A comprehensive search in published English-language 
literature till 2013 involving hemorrhoids was performed to construct this review 
article, which discusses advances in the management of hemorrhoids. This includes 
conservative treatment (life style modification, oral medications, and topical 
treatment), office procedures (rubber band ligation, injection sclerotherapy, infrared 
and radiofrequency coagulation, bipolar diathermy and direct-current electrotherapy, 
cryosurgery, and laser therapy), as well as surgical procedures including diathermy 
hemorrhoidectomy, ligasure hemorrhoidectomy, Harmonic scalpel 
hemorrhoidectomy, hemorrhoidal artery ligation, stapled hemorrhoidopexy (SH), and 
double SH. Results, merits and demerits of the different modalities of treatment of 
hemorrhoids are presented, in addition to the cost of the recent innovations. 
Ketan vagholkar et al. (2018),this publication revealed that Hemorrhoids, best 
described as piles in common language, is one of the most common conditions seen in 
colorectal clinics. Bleeding associated with chronic constipation are the presenting 
features of this condition. Hemorrhoids are best defined as “enlargement and distal 
displacement of the anal cushions.” The abnormal dilatation and irregular distortion of 
the vessels together with damage to the supporting connective tissue is seen within the 
hemorrhoids.A wide variety of therapeutic options have evolved over a period of 
time. However, no single option can be considered as the gold standard of treatment. 
Understanding the mechanisms of hemorrhoid development significantly helps in 
deciding the best therapeutic option. 
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III.6. RATIONALE OF THIS STUDY 
Rathamoolam (Bleeding Hemorrhoid) is one of most prevalent ailments 
associated with significant impact on quality of life. Despite of its prevalence and low 
morbidity, hemorrhoid disease has a high impact on quality of life, and can be 
managed with Siddha medicine.From the review of literature, Rathamoolam has 
mentioned in Yugivaidya chinthamani stanza 650,which could be correlated with 
Bleeding Hemorrhoids in modern medicine based on symptoms. Siddha medicine 
provides the best alternative management as it act on the root cause of the disease.A 
herbal remedy is used to prevent as well as to treat or to promote healing& health. 
Therapeutic objective in Rathamoolam are Arrest bleeding from anus 
(styptic),Relieving constipation (laxative), Subsiding inflammation (anti 
inflammatory), Relieving pain around anus(analgesic),Relieving itching around 
anus(antimicrobial) and increasing Hb level(haemetenic).Recently, various research 
showed that all parts of Nelli(Phyllanthus emblica L) have the above said therapeutic 
action.Nelli Kudineer(Root,Bark,Leaf ,Fruit)is mentioned in Gunapadam Mooligai 
C.S.Murugesu Mudaliyar page no:621 for Rathamoolam. So, I have been selected the 
trial drug Nelli Kudineer(NK) for Rathamoolam(RM) as my dissertation work. 
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CHAPTER-IV 
MATERIALS AND METHODS 
STUDY DESIGN 
          A prospective open labelled Non randomized phase II clinical study. 
STUDY PLACE 
             OPD &IPD of Govt.Siddha Medical College & Hospital,Palayamkottai. 
SAMPLE SIZE 
                   40 patients (20 OP&20 IP) 
STUDY PERIOD 
                 24 months from June 2017 To June 2019. 
ETHICAL CLEARANCE 
The trial was conducted in accordance with Ethical principles that are 
consistent with Good Clinical Practice guidelines and obtained prior approval before 
start of the trial from Institutional Ethical Committee of GSMCH, Palayamkottai. IEC 
number for this Trial is GSMC-IV-IEC/2017/Br-I/10,dated 29.05.2017(Annexure -I) 
Institutional Animal Ethical Committee(IAEC) approval obtained from K.M. College 
of Pharmacy, Madurai. IAEC Number for this trial is 
TNMGRMU/MD(S)/321611010/KMCP/29/2018, dated 01.05.2018 (Annexure -II) 
The trial was applied and registered in Clinical Trial Registry of India. CTRI number 
is CTRI/2018/03/012713, Registered on 21.03.2018(Annexure-III) 
SAMPLE SELECTION 
             The population of study was confirmed the patients who came with the 
clinical features of inclusion criteria in OPD at GSMC,Palayamkottai, they were 
subjected to screening and documented the details using Proforma. 
Inclusion Criteria 
• Age:20-60 years 
• Gender: Both Gender 
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• Patients with Rathamoolam (Bleeding Hemorrhoid) based on the disease 
criteria of Bleeding per anus, Pain around anus, Constipation, Protrusion of 
pile mass, Mucous discharge, Itchy anus and Anemia 
Exclusion Criteria 
• Below 20 years, Above 60 years 
• Sentinel piles 
• Fissure/Fistula in Ano 
• Prolapse of Rectum 
• Malignancy 
• Rectal polyp 
• Chronic Kidney, Liver and Cardiac diseases. 
• Pregnant women. 
Withdrawal Criteria 
• Profuse bleeding 
• Drug reaction 
• Serious illness 
TRIAL MEDICINE: NELLI KUDINEER (NK) 
 The siddha herbal formulation Nelli Kudineer was selected from the Gunapadam 
mooligai siddha text.  
Ingredients of NK 
          Table-IV.1: Ingredients of NK 
Tamil name Botanical 
name 
Family Parts used Therapeutic 
uses 
Nelli Phyllanthus 
emblica L 
Euphorbiaceae Root, 
Bark, 
Fruit, 
Leaf. 
Pandu 
Sobai 
Kamalai 
Magotharam 
Moolam 
Perumpadu 
Megaushnam 
Soolai vali 
Moorchai 
Vaayu 
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Collection and Authentication of Nelli 
The Root, Bark, Fruit and Leaf of Nelli were freshly collected from Tenkasi. It 
was identified and authenticated by Department of Medicinal botany (Annexure-IV) 
Govt. Siddha Medical college, Palayamkottai, Tirunelveli. 
Purification and Preperation of Nelli 
                        The impurities from the plants were removed, cleaned and dried in 
shade. An equal quantity of purified parts were taken and coarsely powdered and 
taken as Kudineer chooranam (KC) form. For the preparation of Kudineer, 25gm of 
the KC was boiled with 500 ml of water till reduced to 100ml of 
Kudineer(Chidambatathanu Pillai, Siddha system of Pharmacopoeia Pg no:34).This 
chooranam is stored in air tight clean container and issued each packets to patients. 
Each packet is contained 50 gm of the Kudineer chooranam. For OP cases one packet 
was given for 7 days and advised for periodical assessment once in seven days for one 
month. For IP cases, the prepared Kudineer is issued directly by me. 
                      Dose:  Kudineer 100ml, OD(morning),Before food. 
                      Duration: 30 days 
          Figure- IV.1: Preperation of NK 
           
                    LEAF                                                     ROOT 
             
                     FRUIT                                                                BARK 
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      KUDINEER CHOORANAM                                         KUDINEER 
Panchabootha aspect of NK 
                 Table IV.2: Panchabootha aspect of NK 
Taste Panchabootham Potency Mukkutram Function 
Sour Mann+Theyu Hot V normalized Proper digestion, Proper 
functioning of Jadarakkini, 
Nourishes blood vessel, Easy 
defaecation 
Astringent Mann+Vayu Cold P normalized Constricting effect, heal 
ulcers, Removes PK 
Sweet Mann+Neer Cold V normalized 
Normalized 
theVP 
Activate 5 sense organs 
Vatham is normalized by Sweet,Sour,Salt.Pitham is normalized by 
Sweet,Astringent,Bitter.Cold potency taste which have no predominant Theyu 
bootha,Tastes are Astringent,Sweet,Bitter.Removes Ratham and Pitham,Increases life 
span, Give pleasure to mind. Earth(Mann) is predominant bootham in Nelli 
Kudineer.It evacuate the thodam within the Intestine by defaecation.It has all the 
qualities of other boothams. 
Basic method used by Siddhars for the preparation of Siddha medicines are 
1. Ekamooligai prayokam 
2. Maarana prayokam 
3. Dravaka prayokam 
4. Cheyaneer prayokam 
5. Muppuchunna prayokam 
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Siddha herbal preparation Nelli Kudineer is prepared based on the 
Ekamooligai prayokam, since it contains only herbal products. Here selecting the 
single drug or combination of drugs on the basis of boothas that is present in the drug 
to normalize the affected thosham. 
PRECLINICAL ANALYSIS OF NK 
Following preclinical studies were carried out and cross checked before 
starting the treatment. 
Biochemical Analysis 
 It had done in Dept.of Biochemistry, GSMCH,Palayamkottai  
Phytochemical Analysis 
      Qualitative phytochemical analysis was done in Biogenix lab Trivandrum. 
Phytochemical screening for Alkaloids, Flavanoids, Saponins, Phenol, Steroids, 
Glycosides, Tannins and Terpenoids were studied. The tests are used for the analysis 
of phytochemicals as described by Harborne and Onwukaeme were carried on 
Alcoholic extract of NK. 
Antimicrobial assay 
Antimicrobial activity by Agar-well diffusion method is used and done in 
Biogenix lab Trivandrum. Materials required for this study were Muller Hinton agar 
medium (1L), Nutrient broth (1L), Streptomycin (10mg/ml), Culture of test organisms 
(E.coli, Staphylococcus aureus) and growth of culture adjusted according to 
McFarland Standard 0.5%. 
 
Pharmacological studies 
Following pharmacological activity studies were done in K.M. College of 
Pharmacy, Madurai Tamilnadu. 
Pharmacological Action  Method Used 
Styptic Blood Cloting Profile 
Laxative Measuring Faeces output 
Analgesic Acetic Acid - Induced Writhing response  
Anti inflammatory Carrageenan induced Paw edema, Pleurisy  
Haemetenic Phenyl hydrazine induced Anaemia 
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Toxicity study 
 Acute toxicity and chronic toxicity of NK is carried out as per OECD-423 
guidelines. In the acute toxicity study, Female wistar albino rats were administered 
60,300,2000mg for 14 days. Chronic toxicity study was carried out for 90 days. 
Toxicity studies were done in K.M.College of Pharmacy, Madurai Tamilnadu. 
ASSESSMENT  
Clinical Assessment 
Raakhi Mehra et.al.(2011) disease criteria is used in this study. Grade is given 
accordingly to intensity and frequency of the criteria. 
• Bleeding per anus 
• Pain around anus 
• Constipation 
• Protrusion of Pile mass 
• Mucous discharge 
• Itchy anus 
• Anemia 
Siddha Assessment 
• Poriyaal arithal 
• Pulanal arithal 
• Vinathal 
• Uyir thaathukkal 
• Udal thaathukkal 
• Envakai thervukal 
• Nilam,Kaalam,Theki 
Investigations 
• Routine blood examination TC, DC, ESR, Hb, Blood sugar, 
S.Cholesterol 
• Routine urine examination: Albumin, Sugar, Deposits 
• Stool examination: Ova,cyst,occult blood     
• Digital Rectal Examination, 
• Proctoscopy.  
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STUDY ENROLMENT AND ASSESSMENT 
 Rathamoolam patients reporting in the OPD are selected based on the 
inclusion criteria. The patients who are enrolled informed about the study of Trial 
drug, possible outcomes and the objectives of the study in their language and terms 
understandable to them and the informed consent is obtained. Detailed history, 
Physical examination, clinical assessment and Investigations were done as per the 
Proforma (Annexure-V). 
TRIAL MONITORING AND TREATMENT. 
 The Guide and Supervisor monitored the progress of the trial. The 
Head of the Department monitored the data entries. On the first day NK chooranam 
packets was given to enrolled OP patients and asked to have regular follow up once in 
seven days for one Month. Nelli Kudineer was given to IP patients directly. The 
clinical assessment and Investigations were done before and after treatment and 
recorded in the prescribed Proforma. All the patients are instructed to follow the 
compatible diet and activities and Yoga and Meditation. 
STATISTICAL ANALYSIS 
The collected data’s are presented in the form of percentage and figures. And 
analyzed using the SPSS. Data was expressed as Mean and Standard deviation. The 
significance of the difference between the mean of the baseline and final examinations 
was tested using the Paired “t” test. A probability value (P-value) of <0.05 was 
considered to be statically significant.  
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CHAPTER-V 
RESULTS AND OBSERVATIONS 
V.I. PRECLINICAL STUDY OF NELLI KUDINEER 
Biochemical Analysis 
  5 gms of the drug was weighed accurately and placed in a 250 ml clean beaker 
then 50 ml of distilled water is added and dissolved well. Then it is boiled well for 
about 10 minutes. It is cooled and filtered in a 100ml volumetric flask and then it is 
made to 100 ml with distilled water. This fluid is taken for analysis. 
           Table -V.1.1: Result of Qualitative biochemical analysis 
Sl 
No. 
EXPERIMENT OBSERVATION INFERENCE 
1.  Test for Calcium White precipitate formed Calcium present  
2.  Test for Sulphate White precipitate formed Sulphate present
 
3.  Test for Chloride White precipitate formed Chloride present 
4.  Test for Carbonate No brisk effervessence is formed Carbonate absent 
5.  Test for Starch No blue colour is formed Starch absent 
6.  Test for Ferric iron No blue colour is formed Ferric Iron absent 
7.  Test for Ferrous Iron Blood red colour is formed Ferrous Iron 
present 
8.  Test for Phosphate No yellow precipitate is formed Phosphate absent 
9.  Test for Albumin No yellow precipitate is fprmed Albumin absent 
10. Tesst for Tannic acid Blueblack precipitate is formed Tannic acid present 
11. Test for Unsaturation It gets decolourised Unsaturated 
compound present 
12. Test for Reducing sugar No colour change occur Reducing sugar 
absent 
13. Test for Amino acid Violet colour is formed Aminoacid present 
14. Test for Zinc No white precipitate is formed Zinc absent 
From Table-V.1.1, Analysis was noted that the presence of  calcium, sulphate, 
Chloride, ferrous iron, tannicacid, unsaturated compound, amino acid and showed 
the absence of carbonate, starch, ferric iron, phosphate, albumin, reducing sugar, zinc. 
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Phytochemical Analysis 
                     Table-V.1.2: Result of Qualitative Phytochemical analysis of NK 
Phytochemicals Observation Inference 
1.Alkaloids An orange red precipitate produced. Presence of alkaloids 
2.Flavanoids No characteristic change. Absence of flavanoids 
3.Phenols A blue or green color was formed. Presence of Phenols  
4.Glycosides A Yellow color was formed. Presence of glycosides  
5.Saponins No characteristic change. Absence of saponins 
6.Steroids A red color was produced in the chloroform 
layer. 
Presence of steroids  
7.Tannins The bluish black color was disappeared in 
the addition of sulfuric acid, no yellow 
color precipitate. 
Presence of tannins 
8.Terpenoids A red color was produced in the chloroform 
layer. 
Presence of terpenoids. 
 The above Table –V.1.2:The qualitative Phytochemical analysis was resulted in  
the presence of alkaloids, phenols, glycosides, steroids, tannins and terpenoids. 
Antimicrobial Assay 
                      Table-V.1.3: Gram Positive (Organism: Staphylococcus aureus) 
Sample Concentration (µg/ml) Zone of inhibition(mm) 
Streptomycin 100µg 27 
 250 Nil 
Nelli Kudineer 500 Nil 
 1000 13 
                     Table-V.1.4: Gram Negative (Organism: E.Coli) 
Sample Concentration (µg/ml) Zone of inhibition(mm) 
Streptomycin 100µg 25 
 250 Nil 
Nelli Kudineer 500 10 
 1000 14 
 
 According to Table- V.1.3 and V.1.4 revealed that NK extract exhibited anti 
microbial activity against E.Coli at concentration of 250 µg/ml was no ZIC and at 
500µg/ml is 10mm zone of inhibition (ZIC) and at 1000µg/ml concentration was 
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14mm zone of inhibition. Antimicrobial activity of NK against Staphylococcus aureus 
at concentration of 250 & 500µg/ml was showed not sensitive to the micro organism 
and at 1000µg/ml zone of inhibition  was 13 mm was observed from my study. 
Pharmacological Activities 
1. Anti-Coagulant activity NK  
                  Table- V.1.5: Effect of NK on Blood clotting profile in wistar rats. 
Groups 
Bleeding 
time (sec) 
 
Clotting 
time (sec) 
 
Prothrombin 
time 
 
Activated 
Thromboplastin 
time 
 
Fibrinogen 
Time 
Normal 
control 85.25±2.15 118.1±3.15 25.30±1.32 26.04±1.40 194.6±3.12 
NK 
100mg/kg 91.20±2.45*a 115.3±2.90*a 24.14±1.26*a 23.10±1.32*a 172.8±3.03*a 
NK 
200mg/kg 87.10±2.35*a 111.2±2.55*a 21.18±1.13*a 16.25±1.20*a 143.9±2.78*a 
Standard 
control 82.40±1.80*a 108.2±1.94*a 18.25±0.92*a 12.55±1.02*a 117.7±2.32*a 
 
Values are expressed as Mean± SEM.(*a Values are significantly different from 
Normal control at P<0.01)  Table-V.1.5  resulted in  analysis of the blood clotting 
profile of control and drug treated  dose of 100 and 200mg/kg  of NK was possess 
significant reduction in clotting  time, bleeding time, prothrombin time, partial 
thromboplastin  time  and  fibrogen time when compared to the control rats. 
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2. Laxative Action of NK 
                  Table-V.1.6 Laxative action of NK 
Groups Drug treatment  Faeces output (gms) 
I Control Saline (10ml/kg) 3.80±0.40 
II Sodium picosulfate (5mg/kg) 12.30±1.24* 
III Nelli Kudineer100mg/kg 10.38±0.90** 
IV Nelli Kudineer200mg/kg 11.45±0.96*** 
Values are in Mean ± SEM; (n = 6); *P < 0.05,**P < 0.01, *** P < 0.001 Vs 
Control Table-V.1.6 illustrated that  NK was studied for laxative action in Wistar 
Albino rats. The laxative action was assessed by measuring the wet faeces in all test 
drug administered groups. The NK showed significant (P<0.01) dose dependent 
laxative action as compare to normal control animals. The laxative activity produced 
by the NK was similar to that of the reference control sodium picosulfate.  NK 
produced significant and dose dependant increase in faeces output of rats. Sodium 
picosulfate is a member of the poly phenolic group of stimulant laxatives. Following 
oral administration, it is converted in the colon to an active form through the action of 
bacterial enzymes. As a result, its effects are directed the colon, where it stimulates 
peristalsis and reduces water reabsorption leading to the softening of stools 
3. Evaluation of Analgesic Activity of NK. 
           Table-V.1.7: Effects of NK on Acetic acid–induced writhing response . 
Groups 
(N=6 in each Gp) 
Treatment Number of writhing 
movements (Mean ± S.E) 
Percentage % 
Group I Distilled water 31.00 ± 2.48   
Group II Diclofenac sodium 
10mg/kg 
 5.72 ± 0.89*b 
 
81.54% 
Group III 100mg/kg NK 14.20 ± 1.63*b 54.19% 
Group IV 200mg/kg NK 13.12 ± 1.28*b 57.67% 
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Values are expressed as mean ± SEM.(*b: Values are significantly different 
from control      G2 at P<0.01) Table-V.1.7 showed that the different doses of NK had 
significantly noted analgesic effects in the animals. The doses of 100 & 200 mg/kg 
were significant & comparable with effect of Diclofenac sodium in analgesic activity 
.Groups of rats (n=6), were administered with 100 & 200 mg/kg of NK,10 mg /Kg 
Diclofenac  sodium as positive control group & 1 ml distilled water as negative 
control group. After 30 minutes the animals were administered with i.p. injection of 
0.1ml acetic acid (0.6%).Then the count of abdominal contractions of animals during 
30 minutes after acetic acid injection was reported and the percentage analgesic 
activity (PAA) was calculated. 
4. Evaluation of Carrageenan induced Anti-inflammatory Activity of NK. 
             Table-V.1.8: Effect of NK on Carrageenan Induced Rat Paw Edema. 
Treatment  
group 
Dose 
(mg/kg, p.o.) 
Mean increase 
in paw volume (ml) 
% Decrease in 
paw volume 
Normal control (G1) 10ml/kg saline 0.86 ± 0.06   
Toxic control (G2) 0.1 ml, 1% 
carrageenan 
3.38 ± 0.24*a 
 
 
Standard control (G3) 10mg/kg 
Indomethacin 
1.26 ± 0.12*b 
 
62.72% 
Treatment control (G4) 100mg/kg NK 1.38 ± 0.16*b  59.17% 
Treatment control (G5) 200mg/kg NK 1.33 ± 0.14*b  60.65% 
Values are expressed as mean ± SEM. Values were compared by using 
analysis of variance (ANOVA) followed by Newman-Keul's multiple range tests.* (a) 
Values are significantly different from normal control G1 at P<0.01.* (b) Values are 
significantly different from Toxic  control G2 at  P<0.01.The above Table-V.1.8 
showed the  effect of NK on Carrageenan-induced  Paw edema in rats. The results 
obtained indicate that NK had significant anti-inflammatory activity in rats. The NK 
reduced the edema induced by carrageenan by 59.17% and 60.65%  on oral 
administration at 100 and 200 mg/kg as compared to the untreated control group. 
Indomethacin at 10 mg/kg inhibited the edema volume by 62.72%. The anti-
inflammatory activity  were expressed as Mean increase in paw diameter ± SD. 
Results were analyzed using one way ANOVA. Differences were considered as 
statistically significant at P < 0.05 are compared to control 
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     Table-V.1.9:Effect of NK on Carrageenan Induced Pleurisy in Rats. 
Treatment  
 
Dose 
(mg/kg, p.o.) 
Pleural exudates 
(ml) 
Leukocytes 
(×103 cells/ml) 
Normal control 10ml/kg saline 0.14±0.05 0.32±0.02 
Toxic control 0.1 ml, 1% carrageenan 0.36±0.11*a 4.20±0.33*a 
Standard control 10mg/kg Indomethacin 0.14±0.03*b 0.46±0.06*b 
Treatment control 100mg/kg NK 0.21±0.08*b 0.51±0.07*b 
Treatment control 200mg/kg NK 0.13±0.02*b 0.48±0.05*b 
Values are expressed as mean ± SEM. Values were compared by using 
analysis of variance (ANOVA) followed by Newman-Keul's multiple range tests.* (a) 
Values are significantly different from normal control G1 at P<0.01.*(b) Values are 
significantly different from Toxic  control G2 at  P<0.01.Table-V.1.9 showed that the 
volume of pleural exudates in the toxic control group was 0.36±0.11 ml. Animals 
treated with NK(100 and 200 mg/kg, p.o.) the pleural exudates was 0.21±0.08 ml and 
0.13±0.02.Treatment with Indomethacin(10 mg/kg, p.o.) produced the exudates of 
0.14±0.03 ml. The leukocyte count for the control group was found to be 
4.20±0.33×103 cells/ml. Animals treated with the trial drug and  and standard 
produced a leukocyte migration of 0.51±0.07×103,0.48±0.05X103 and 0.46±0.06×103 
cells/ml respectively.  
5. Haematinic activity of NK in Phenyl hydrazine induced Anaemic rats  
             TableV.1.10: Result in Hematological Parameters of Rats   
Parameters G1 G2 G3 G4 G5 
HB g/dl 14.40±1.40 8.28±0.94** 12.10±1.05** 12.45±1.18** 14.08±1.32** 
PCV (%) 49.15±2.20 41.24±1.92 44.30±2.02** 45.18±2.08** 48.35±2.14** 
RBC 4.25±0.32 4.08±0.24  4.40±0.54 4.48±0.59 4.66±0.68 
MCV 76.08±2.18 92.40±2.94 86.05±2.48** 82.22±2.39** 79.35±2.28 
MCH 26.15±2.45 33.84±2.90 31.55±2.85 29.28±2.68 27.46±2.58 
MCHC g/dl 33.10±1.18 32.56±1.04 33.38±1.26 34.05±1.35 34.55±1.48 
Values are mean±S.E.M.**P<0.01Vs Control N=6.Phenyl hydrazine is used for 
the induction of haemolytic anaemia and the study of its mechanism in many species 
including rats.Phenyl free radical produced via the 2- electron oxidation of  phenyl 
hydrazine by oxyhemoglobin. This free radical binds with red cell and hemolyses it 
rapidly and converts oxyhemoglobin  into methemoglobin. Thus, PHZ-induced 
hemolytic injury seems to be derived from oxidative alterations to red blood cell 
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proteins rather than to membrane lipids.The RBC,Hb,and PCV of rats administered 
Phenyl hydrazine decreased significantly (P <0.01) while the MCV and MCH 
increased giving rise to macrocytic anaemia (P<0.05).NK at oral doses of 100mg and 
200mg showed increased in haemoglobin level is represented in Table-V.1.10. 
Significant increase in Hb(p<0.01)was observed when compared to positive control 
and it was comparable to standard drug used in this study. Phenyl hydrazine altered the 
haematological parameters by haemolysis characterized by decrease in haemoglobin 
concentration, total RBC and PCV on day 7.However,the haematological parameters 
were restored to normal range after treatment with NK at single oral doses of 100mg 
and 200mg for 14 days. Effective changes were observed after  one week of treatment 
of anaemic rats with NK at oral doses of 100mg and 200mg reversed the influence of  
Phenyl hydrazine resulting to a significant  (P<0.05) increase in RBC, Hb and PCV. 
The Hb, RBC and PCV reached near normal at the second week of the treatment. Also 
the recovery was progressive such that after 1week of continuous treatment, the Hb 
concentration and PCV were higher in the treated groups than in the normal control 
group. 
Toxicity study with NK 
A: Acute toxicity study with NK 
                 Table-V.1.11: Acute toxicity study with NK 
Group Dose (mg.kg-1) Sign of Toxicity (ST.NB-1) Mortality (D.S-1) 
I              0                      0/3            0/3 
II            300                      0/3            0/3 
III           2000                      0/3            0/3 
 
      ST- sign of toxicity; NB- normal behaviour; D- died; S- survive.  Values are 
expressed as number of animals (n=3). The acute toxicity of NK was evaluated using 
OECD- 423 guidelines. There was no mortality or morbidity observed in Female 
wistar albino rats through the 15-days period following single oral administration at 
all selected dose levels of the NK(Table-V.1.11). The animals did not show any 
changes in the general appearance during the observation period. Morphological 
characteristics such as fur, skin, eyes and nose appeared normal. No tremors, 
convulsion, salivation, diarrhea, lethargy or unusual behaviors such as self mutilation, 
walking backward and so forth were observed. Gait and posture, reactivity to handling 
or sensory stimuli, grip strength was also normal.  
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B. Chronic toxicity study with NK 
6.B.1: Effects of NK on Body weight changes in Rats. 
                   Table-V.1.12: Effects of NK on Body weight changes in Rats. 
Treatment Day 1 Day 30 Day 60 Day 90 
Control 188.15±6.8 188.45  ±6.20 197.15 ±6.35 197.7±6.58 
NK:50 mg.kg-1 195.30 ±6.4 194.30  ±6.30 199.25 ±6.70 199.30±6.72* 
NK:100 mg.kg-1 187.35 ±5.7 190.30  ±6.40 197.55  ±7.10 198.36±6.30* 
NK:200 mg.kg-1 196.30  ±7.2 199.15±6.50 199.90  ±7.20** 207.45±7.26** 
NK:400 mg.kg-1 188.65  ±6.05 193.15 ±5.60 196.60  ±6.35** 208.66±7.38** 
 
Table-V.1.12 showed the effects of NK on body weight changes in rats. Group 
I animals  were treated with normal saline (5 ml.kg-1), group II animals with 50 
mg.kg-1 of NK,  group III animals with 100 mg.kg-1 of NK, group IV animals with 
200 mg.kg-1 of NK, group V animals with 400 mg.kg-1NK. The values are expressed 
as mean ± S.E.M. n=6. The results of group I were compared with other groups such 
as II, III, IV, and V.   The statistical analysis was carried out using one way ANOVA 
method, where **P<0.01 *P<0.05. The effect of NK was observed for their effect on 
the body weight changes from the study it was observed that, there was significant 
increase (p<0.05) in body weight in all the animals were observed. 
6.B.2: Effect of NK on Kidney, Heart, Liver and Brain in rats 
Table-V.1.13: The changes in internal organs with NK 
Treatment Heart (gms) Kidney (gms) Liver (gms) Brain (gms)   
Control 0.35 ± 0.05 0.65± 0.03 3.36± 0.05 0.68± 0.05 
NK@50 mg.kg-1 0.36± 0.02 0.81± 0.03 3.48± 0.03 0.72± 0.3 
NK@100 mg.kg-1 0.37± 0.06 0.79± 0.04 3.42±0.02 0.69± 0.2 
NK@ 200 mg.kg-1 0.36± 0.04 0.74± 0.02 3.38± 0.02 0.76± 0.05 
NK@400 mg.kg-1 0.35± 0.03 0.75± 0.03 3.41± 0.03 0.78± 0.05 
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Table-V.1.13 showed the effects of NK on kidney, heart, liver and brain of the 
rats. Where, group I animal treated with normal saline (5 ml.kg-1), group II animals 
with 50 mg.kg-1 of NK, group III animals with 100 mg.kg-1 of NK, group IV animals 
with 200 mg.kg-1 of NK, group V animals with 400 mg.kg-1NK.  The values are 
expressed as mean ± S.E.M. n=6.   The results of group I were compared with other 
groups such as II, III, IV,and V.  The statistical analysis was carried out using one 
way ANOVA method, where **P<0.01.From the study it was clear that, significant 
(p<0.01) changes in the weights of various organs of the animals occurred with higher 
doses of the extract (400 mg.kg-1 bwt), but macroscopic examinations did not show 
any changes in color of the organs of the treated animals compared with the control. 
6.B.3: Effect of NK on biochemical profiles of Glucose and Lipids in rats  
         Table-V.1.14: Effects of NK on Biochemical parameters of Glucose and Lipids  
Treatment group Glucose (mg.dl-1) 
Cholesterol 
(mg.dl-1) 
Triglyceride 
(mg.dl-1) 
HDL 
(mg.dl-1) 
LDL 
(mg.dl-1) 
Control 97.65± 0.62 41.62± 0.56 30.25± 0.45 138.25± 0.55 84.15±1.72 
NK@ 50 mg.kg-1 95.50± 0.56 27.85± 0.25* 15.22± 0.23* 178.28± 0.65* 72.59±1.28 
NK@ 100 mg.kg-1 92.45± 0.47 29.74± 0.26* 17.42± 0.28* 168.18±0.78* 69.84±1.10 
NK@ 200 mg.kg-1 93.25± 0.55** 35.18± 0.30 19.84± 0.38* 187.30± 0.84* 48.60±1.30 
NK@ 400 mg.kg-1 87.25± 0.45** 34.78± 0.28 20.28± 0.34* 185.2± 0.85* 46.50±0.84 
 
Table-V.1.14 revealed the effect of NK on Glucose and Lipids level. Group I animals 
treated with normal saline (5 ml.kg-1), group II animals with 50 mg.kg-1 of NK,  group 
III animals with 100 mg.kg-1 of NK, group IV animals with 200 mg.kg-1 of NK, group 
V animals with 400 mg.kg-1NK. The values are expressed as mean ± S.E.M. n=6.   
The results of group I were compared with other groups such as II, III, IV, and V.  
The statistical analysis was carried out using one way ANOVA method, where 
**P<0.01 *P<0.05. The Significant decrease (p<0.05) in the plasma total cholesterol 
(TC), triglyceride (TG) and LDL-cholesterol levels were observed.   But a significant 
increase (p<0.05) in HDL-cholesterol levels were observed in all the treated animals 
compared with the control animals 
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6.B.4: Effects of NK on Biochemical Parameters of Liver 
          Table-V.1.15:The effects of NK on biochemical parameters of Liver 
 
Treatment group AST (IU.l-1) 
ALT 
(IU.l-1) 
ALP 
(IU.l-1) 
TP 
(g.l-1) 
ALBUMIN 
(g.l-1) 
Control 320.5±12.40 68.5± 3.18 253.58± 8.80 69.85± 3.32 39.15±2.35 
NK@50 mg.kg-1 309.0±9.50** 66.5± 2.20** 266.10± 2.75** 70.30± 2.32 36.30±2.65 
NK@ 100 mg.kg-1 310.3±7.20** 64.1± 3.15** 260.18± 6.70** 80.15± 2.82 38.30±3.05 
NK@ 200 mg.kg-1 305.4±7.95 59.4± 2.90 265.00± 5.20 69.25± 3.32 40.20±2.75 
NK@ 400 mg.kg-1 315.2± 8.20 61.3± 3.52 269.40± 4.40 74.05± 2.58 39.48±2.70 
  A study on the effects (Table-V.1.15) of NK on biochemical parameters of liver 
such as AST, ALT, ALP, TP and Albumin rats was tested. where, group I animals 
were treated with normal saline (5ml.kg-1),  group II animals with 50 mg.kg-1 of NK, 
group III animals with 100 mg.kg-1of NK, group IV animals with 200 mg.kg-1 of NK,  
and group V animals with 400 mg.kg-1NK.The values are expressed as mean ± S.E.M. 
n=6.   The results of group I were compared with other groups such as II, III, IV, and 
V.   The statistical analysis was carried out using one way ANOVA method, where 
**P<0.01 *P<0.05.AST, ALT and ALP levels were also normal in the NK treated 
animals. From the results of biochemical study there was no evidence of severe 
toxicity associated with the administration of higher concentration of NK. 
6.B.5. Effect of NK on Hematological parameters Hb,RBC,WBC,Calcium in rats   
            Table-V.1.16:Effects of NK on Hematological parameters  
Treatment group Hemoglobin (mg.dl-1) 
RBC 
(106 /mm3) 
WBC 
(106 /mm3) 
Calcium 
(mg.dl-1) 
Control 12.3± 0.25 9.15± 0.02 11.45± 0.05  9.45 ±0.02 
NK@ 50 mg.kg-1 13.5± 0.26* 9.50± 0.04*   9.55± 0.01*  9.21 ±0.02 
NK@ 100 mg.kg-1 13.3± 0.15* 9.55± 0.02*   8.35± 0.32*  9.27 ±0.20 
NK@ 200 mg.kg-1 11.7± 0.20* 8.33± 0.12* 11.45± 0.03*  9.61 ±0.13 
NK@ 400 mg.kg-1 12.5± 0.35* 8.51± 0.45*  10.55±0.13*  9.75 ±0.02 
The effects of NK were observed (Table-V.1.16) for its effect on 
hematological parameters on the experimental rats. From the study it was evident that, 
a significant increase (p<0.01) were observed in the hemoglobin contents and  RBC 
count  in the group treated with NK 200 mg.kg-1 body weight and a significant 
decrease of the parameters occurred in the group treated with 400 mg.kg-1 bw 
compared with the control.   There was no significant change in the calcium level in 
all the treated animals compared to the control. Where, group I animal treated with 
normal saline (5 ml.kg1), group II animals with 50 mg.kg-1 of NK, group III animals 
with 100 mg.kg-1 of NK,   group IV animals with 200 mg.kg-1 of NK, and group V 
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animals with  400 mg.kg-1NK. The values are expressed as mean ± S.E.M. n=6. The 
results of group I were compared with other groups such as II, III, IV and V.   The 
statistical analysis was carried out using one way ANOVA method, where *P<0.05. 
V.2. CLINICAL STUDY 
This study was hospital based Prospective open labelled phase II Non-
randomized clinical study of Nelli Kudineer for Rathamoolam (Bleeding 
Hemorrhoids). This study was covered 40 Rathamoolam patients, they were came  
from different parts of Tirunelveli. The Trial drug NK was given to selected patients 
and evaluated its therapeutic efficacy clinically for Rathamoolam. 
The results were observed with respect to the following criteria by clinical study 
on 20 outpatients and 20 inpatients of both sexes. The criteria were, 
1. Distribution of Gender 
2. Distribution of Age 
3. Distribution of Religion 
4. Distribution of Educational status 
5. Distribution of Occupation 
6. Distribution of Socio economic status  
7. Distribution of Marital status 
8. Distribution of Family History 
9. Distribution of Dietary habits 
10. Distribution of Addiction 
11. Distribution of Sleep 
12. Distribution of History of previous treatment 
13. Distribution of Nilam 
14. Distribution of Kaalam 
15. Distribution of Thegi 
16. Distribution of Gunam 
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17. Distribution of Kanmenthiriyam 
18. Distribution of Aasayangal 
19. Distribution of Kosangal 
20. Distribution of Uyirthathukkal 
21. Distribution of Udalthathukkal 
22. Distribution of Naadi 
23. Distribution of Envakaithervu 
24. Distribution of Neikkuri 
25. Distribution of Clinical presentation 
26. Distribution of Disease criteria 
27. Distribution of Duration of illness 
28. Distribution of Aggravating factors 
29. Distribution of Degree of Hemorrhoids 
30. Distribution of Change of Symptoms 
31. Distribution of Hb level 
32. Distribution of Gradation of Results   
  
 V.2.1.Distribution of Gender
 
                       Table-V.2.1: Distribution of gender 
Gender                   
No of cases
Male 
Female 
Total 
 
                          Figure
                 Above Table
and 50% were Male, among 20 IP 85% were Female and 15% were Male.
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-V.2.1: Distribution of Gender 
-V.2.1&Figure-V.2.1 shows among 20 OP, 50% were Female 
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 V.2.2: Distribution of Age
 
Table
 
Age group(years)
21-30 
31-40 
41-50 
51-60 
Total 
   
 Above Table-V.2.2 and Figure
were between the age group of 41
the age group of 51-60 i.e.60%.
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-V.2.2: Distribution of Age and its percentage
 
OP IP
Number of cases % Number of cases
6 30 2 
4 20 4 
7 35 2 
3 15 12 
20 100 20 
 
Figure-V.2.2.Distribution of Age 
-V.2.2 Illustrated that among OP most of the cases 
-50 i.e.35%. The most of the IP cases were between 
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V.2.3: Distribution of Religion
 
       Table-V.2.3: Distribution of Religion
Religion 
Hindu 
Muslim 
Christian 
Total 
 
                              Figure
 
From the Tabl
60% were Hindus, 25% were muslims and 15% were Christians. Among IP 
populations 90% were Hindus and 10% were Christians.
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OP IP 
No of cases % No of cases 
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3 15 2 
20 100 20 
-V.2.3: Distribution of Religion 
e-V.2.3 and Figure-V.2.3 revealed that among OP population 
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V.2.4: Distribution of Educational status
                   Table-V.2.4: Educational status and its perc
Educational status
Primary 
Middle school 
High school 
College 
Total 
   
                              Figure
 
  Above Table-V.2.4 and Figure
college level education. 60% of IP cases had the high school level education. 
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entage 
 OP IP 
No of 
cases 
% No of 
cases
1 5 1 
2 10 5 
6 30 12 
11 55 2 
20 100 20 
-V.2.4: Distribution of Educational status 
-V.2.4 showed that 55% of OP cases had the 
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 V.2.5: Distribution of Occupation
                   Table-V.2.5: Distribution of Occupation and its p
 
              Above Table
sedentary workers (35%)
labour (45%) and sedentary work (25%).
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Figure-V.2.5:Distribution of Occupation
 
-V.2.5 and Figure-V.2.5. revealed that h
 and labours (30%) among OP. Among IP high prevalence in 
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 V.2.6: Distribution of Socio economic status
          Table-V.2.6: Distribution of Socio economic st
Socio economic status
Upper 
Middle 
Lower 
Total 
 
           Figure-V.2.6: Distribution of Socio economic status
Above Table 
middle economic family in OP population
IP population(60%). 
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atus and its Percentage
 OP IP
No of 
cases 
% No of 
cases
 4 20 0 
10 50 8 
6 30 12
20 100 20
 
-V.2.6and Figure-V.2.6showed that High 
 (50%) and from Lower economic status in 
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 V.2.7: Distribution of Marital status
Table-V.2.7: Distribution of Marital status and 
 
 
 
         
   
Figure
 
Table -V.2.7and Figure
and 95% were married in IP population.
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Total 
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its Percentage
-V.2.7: Distribution of Marital status 
- V.2.7showed that 65% OP population were
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20 100 20 
 
 
 
 married 
 
% 
95 
5 
100 
 V.2.8: Distribution of Family history of Hemorrhoids
 
  Table-V.2.8: Distribution of Family history of Hemorrhoids and its Percentage
Family history of Hemorrhoids
Yes 
No 
Total 
 
               Figure-V.2.8: Distribution of Family history of Hemorrhoids
 
Table-V.2.8 and Figure
history of Hemorrhoids and 30% of IP population had family 
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 OP IP 
No of 
cases 
% No of 
cases
8 40 6 
12 60 14 
20 100 20 
-V.2.8 showed that 40% OP population had family 
history of Hemorrhoids.
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 V.2.9: Distribution of Dietary habits
   Table-V.2.9: Distribution of Dietary habits
Dietary habits 
Vegetarian 
Mixed diet 
Timely 
Untimely food 
 
            Figure-V.2.9: Distribution of Dietary habits
 Table-V.2.9 and Figure
include Mixed diet(75%),Untime
prevalence of dietary habits include Mixed
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-V.2.9 revealed that high prevalence
ly food(80%) among OP cases. In IP cases, high 
 diet(90%),Untimely food(85%).
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 V.2.10: Distribution of Addiction
    Table-V.2.10: Distribution of Addiction
 
Addiction 
Smoking 
Alcohol 
Tobacco chewing 
Coffee 
Tea 
 
 
                  Figure-V.2.10: Distribution of Addiction
Table-V.2.10 and Figure
addiction and 40% cases have coffee addiction. Among IP population, 55% have tea 
addiction and 45% have coffee addiction.
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-V.2.10 revealed that 60% OP cases have tea 
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 V.2.11: Distribution of Sleep
Sleep 
Normal 
Disturbed 
Insomnia 
Total 
 
                     Figure-V.2.11: Distribution of Sleep
 Above Table-V.2.11and Figure
OP cases and 50% of IP cases.
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Table-V.2.11: Distribution of sleep 
OP IP 
No of 
cases 
% No of 
cases
13 65 10 
6 30 10 
1 5 0 
20 100 20 
 
-V.2.11 showed that sleep was disturbed in 30% of 
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 V.2.12.Distribution of 
 
Table-V.2.12: Distribution of 
 
Previous treatment
Yes 
No 
 
           Figure-V.2.12: Distribution of history of previous treatment
Above Table-V.2.12 and Figure
were had history of previous treatment and among IP
previous treatment. 
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History of previous treatment 
History of previous treatment 
 OP IP 
No of 
cases 
% No of 
cases 
6 30 8 
14 70 12 
 
-V.2.12 revealed that, In OP population 30% 
 40% were had history of 
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 V.2.13: Distribution of Nilam
             Table-V.2.13: Distribution of Nilam
Nilam 
Kurinchii(Hilly area)
Mullai(Forest area)
Marutham(Fertile land)
Neithal(Coastal land)
Paalai(Arid area) 
Total 
 
            Figure: V.2.13 Distribution of Nilam
Above Table-V.2.13 and Figure
were from Marutha nilam and 20% were 
from Marutha nilam and 35% were from Neithal.
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-V.2.13revealed that, In OP population 75% 
from Neithal, In IP population 65% were 
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 V.2.14: Distribution of Kaalam
            Table-V.2.14: Distribution of Kaalam
Kaalam 
Kaar(Aug15-Oct14) 
Koothir(oct15-Dec14)
Munpani(Dec15-Feb14)
Pinpani(Feb15-Apr14)
Ilavenil(Apr15-Jun14)
Mudhuvenil(Jun15-Aug14)
Total 
 
               Figure-V.2.14: Distribution of Kaalam
Above Table 
population,35% were affected in Ilavenil and Muthuvenil(30%) kaalam, Among IP 
population, 30% cases affected in koothir,20% affected in Munpani and Pinpani 
kaalam 
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-V.2.14 and Figure- V.2.14showed that Among OP 
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 V.2.15: Distribution of Theki
     Table-V.2.15: Distribution of Theki
Theki 
Vatha pitham 
Vatha kapam 
Pitha vatham 
Pitha kapam 
Kapa pitham 
Total 
                   Figure-V.2.15: Distribution of Theki 
AboveTable-V.2.15 and Figure
Vatha theki and 40% patients were Vatha Pitha theki among OP cases.50% cases 
were Pitha vatha theki and 35% cases were Vatha Pitha Theki amo
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-V.2.15illustrated that 45 %patients were Pitha 
ng IP.
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 V.2.16: Distribution of Gunam
Gunam 
Satwa 
Rajas 
Thamas 
Total 
 
 
                        Figure-
Above Table 
affected patients in IP & OP having Rajogunam.
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Table-V.2.16: Distribution of Gunam 
OP IP 
No of 
cases 
% No of 
cases
- - - 
20 100 20 
- - - 
20 100 20 
V.2.16:  Distribution of Gunam 
-V.2.17 and Figure- V.2.17 showed that 100% of the 
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 V.2.17: Distribution of Kanmethiriyam
         Table-V.2.17: Distribution of Kanmethiriyam
Kanmenthiriyam
Kai 
Kaal 
Vaai 
Eruvai 
Karuvai 
 
                  Figure-V.2.17:Distribution of Kanmenthiriyam
Above Table -
was affected in 100% cases,, among 20 
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V.2.17 and Figure- V.2.17 showed that among 20 OP, eruvai  
IP eruvai  was affected in 100% cases.
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 V.2.18: Distribution of Aasayangal
 
Aasayangal
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Pakirvasayam 
Salavasayam 
Malavasayam 
Sukkilavasayam 
 
        Figure -V.2.18:Distribution of Aasayangal
Above Table 
amarvasayam  was affected in 60% cases, pakirvasayam was affected in 35% cases, 
malavasayam was affected in
in 45% cases, pakirvasayam was affected in 25% cases, malavasayam was affected in 
100% cases. 
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Table-V.2.18: Distribution of Aasayangal 
 
OP IP
No of 
cases 
% No of 
cases
12 60 9 
7 35 5 
0 0 0 
20 100 20
0 0 0 
 
-V.2.18 and Figure- V.2.18 showed that among 20 OP, 
 100% cases, among 20 IP, amarvasayam  was affected 
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V.2.19: Distribution of Kosangal
      Table-V.2.19: Distribution of Kosangal
Kosangal
Annamayam 
Piranamayam 
Manonmayam 
Vignaanamayam 
Ananthamayam 
 
        Figure- V.2.19: Distribution of Kosangal
Above Table 
Annamayakosam  was affected in 60% cases, pi
cases, among 20 IP, Annamayakosam  was affected in 60% cases, piranamayam was 
affected in 40% cases.
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-V.2.19 and Figure- V.2.19 showed that among 20 OP, 
ranamayam was affected in 40
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V.2.20: Distribution of Uyir thaathukkal 
                 Table-V.2.20: Distribution of Uyir thaathukkal 
Uyir thaathukkal OP IP 
No of 
cases 
% No of 
cases 
% 
Vatham 
    
•        Pranan 
12 60 9 45 
•        Abanan 
20 100 20 100 
•        Viyanan 
8 40 6 30 
•        Uthanan 
- - - - 
•        Samanan 
10 50 12 60 
•        Naagan 
- - - - 
•        Koorman 
- - - - 
•        Kirukiran 
12 60 9 45 
•        Devathathan 
12 60 9 45 
•        Dhananjeyan 
- - - - 
Pitham 
•        Analakam 
12 60 10 50 
•        Ranjakam 
12 60 4 70 
•        Sathakam 
8 40 7 35 
•        Prasakam 
- - - - 
•        Aalosakam 
- - - - 
Kapam 
•        Avalampakam 
- - - - 
•        Kilethakam 
12 60 14 70 
•        Bothakam 
- - - - 
•        Tharpakam 
- - - - 
•        Santhikam 
- - - - 
         
 
                       Figure- V.2.20: Distribution of 
 
 
Above Table-V.2.20 and Figure
was affected in 60% cases, Abanan was affected in 100% cases, Vyanan was affected 
in 40% ,samanan was affected in 50,Kirukaran was affected in 50%,Devadathan was 
affected in 60%,Analagam was affected in 60%,Ranjagam was affected in 
60%,Sathagam was affected in 40%
Abanan was affected in 100% cases, Pranan was affected in 45% ca
affected in 30%, samanan was affected i
Devadathan was affected in 45%,Analagam was affected in 50%,Ranjagam was 
affected in 70%,Sathagam was affected in 35%,Kilethagam was affected in 70%,
 
60
100
40
0
5045
100
30
0
0
20
40
60
80
100
120
P
ra
n
a
n
A
b
a
n
a
n
V
y
a
n
a
n
U
th
a
n
a
n
S
a
m
a
n
a
n
VAHAM
Distribution of Uyir thaathukkal
76 
Uyir thathukkal 
-V.2.20 showed that among 20 OP, Pranan 
,Kilethagam was affected in 60%. A
n 60%,Kirukaran was affected in 45%,
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 V.2.21: Distribution of Udal thathukkal
      Table-V.2.21: Distrib
Udal thathukkal
Saaram 
Senneer 
Oon 
Kozhuppu 
Enbu 
Moolai 
Sukkilam/Suronitham 
 
 
                      Figure-V.21: 
Above Table -V.2.21 and Figure
saaram was affected in 60% cases, senneer was affected in 60% cases, among 20 IP 
saaram was affected in 45% cases, senneer was affected in 70% cases.
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 V.2.22: Distribution of Naadi
      Table-V.2.22: Distribution of Naadi
Naadi 
Vatham 
Pitham 
VathaPitha 
PithaVatha 
PithaKapa 
Total 
 
                          Figure : V.2.22: Distribution of Naadi
 Above Table -V.2.22 and Figure
having Pithavatha naadi
naadi and amoung 20 IP cases
Vatha naadi, 10% were 
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OP IP 
No of 
cases 
% No of 
cases 
1 5 4 
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6 30 2 
10 50 12 
1 5 0 
20 100 20 
 
- V.2.22 showed that among 20 OP 50% were 
 30% were having Vathapitha naadi, 10% were 
, 60% were having Pithavatha naadi
having Pitha naadi  & Vathapitha naadi. 
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 V.2.23: Distribution of Envakai thervu
Table
Envagai thervu 
Sparisam 
Naa 
Niram 
Mozhi 
Vizhi 
Malam 
Moothiram 
                                Figure
Above Table-V.2.23 and Figure
Sparism was affected in 60%, Naa was affected in 30%, niram was affected in 30%, 
Vizhi was affected in 30%, Malam was affected in 100%, Moothiram was affected in 
35%. Among 20 IP cases Sparism was affected in 55%, Naa was affected in
niram was affected in 45%, Vizhi was affected in 50%, Malam was affected in 100%, 
Moothiram was affected in 30%.
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-V.2.23: Distribution of Envakai thervu 
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-V.2.23: Distribution of Envakai thervu 
-V.2.23 showed that among 20 OP cases 
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 V.2.24: Distribution of Neikkuri
        Table-V.2.24: Distribution of Neikkuri
Neikkuri 
Vatha neer 
Pitha neer 
Kapa neer 
Pitha Vatha neer 
Kapa Pitha neer 
Challadaikann  
Total 
 
                                Figure
Above Table -V.2.24 and 
were having Vatha neer
neer, 5% were having
were  having vathaneer,
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-:V.2.24: Distribution of Neikkuri 
Figure- V.2.24showed that among 20 OP cases
, 35% were having Pitha neer, 40% were 
 Kapa neer & Kapapitha neer. Among 20 IP population,
 20% were having pithaneer, 60% were Pithavathaneer.
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 V.2.25: Distribution of Clinical presentation
                  Table-V.2.25: Distribution of Clinical presentation and its Percentage
Parameter 
Classical:7 Criteria
Confirmative:6 Criteria
Clinical:5 Criteria
Diagnostic:4Criteria
Suggestive:3Criteria
 
                   Figure-V.2.25:  Distribution of clinical presentation
Table-V.2.25 and Figure
were according to clinical 
according to diagnostic criteria and 10% according to confirmative and suggestive 
criteria respectively. 3
criteria and 25% cases
diagnostic criteria among IP cases.
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-V.2.25 showed that 60% cases of clinical presentation 
criteria in OP and 15% cases of clinical presentation were 
5% cases of clinical presentation were according to Clinical 
 were according to classical and 20% cases according to 
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 V.2.26: Distribution of Disease criteria
                Table-V.2.26: Distribution of Disease criteria
Disease criteria 
Bleeding per anus 
Pain around anus 
Constipation 
Protrusion of Pile mass 
Mucous discharge  
Itching around anus 
Anemia 
                       Figure-V.2.26: Distribution of Disease criteria
Above Table-V.2.26 and Figure
symptoms were Bleeding per anus, Constipation and Protrusio
Rathamoolam (100%).
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-V.2.26 revealed that high prevalence of 
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 V.2.27: Distribution of Duration of 
        Table-V.2.27: Distribution of Duration of illness and its Percentage
Duration of illness 
0 Months-6 Months 
6 Months-1 Year 
1 Year-2 Year 
2 Year-3 Year 
Total 
 
                   Figure-:V.2.27: Distribution of Duration of illness
Above Table-V.2.27 and Figure
20 OP 50% patients were suffering from six
year, 5% were suffering from 
20 IP 20% patients were suffering from 
year, 15% were suffering from 
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-V.2.27 showed that among 40 patients, out of 
 months, 30% were suffering from one
two years, 15% were suffering from 
six months, 50% were suffering from one
two years,15% were suffering from three
-6 6 Months-1 Year 1 Year-2 Years 2 Years
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 V.2.28: Distribution of A
Table-V.2.28: Distribution of 
Aggravating factors of Rathamoolam
Excessive straining at stool
Prolonged sitting 
Prolonged standing 
Excess heat exposure 
Excess cold exposure 
Change of dietary habits
Psychic disturbance 
           Figure-V.2.28: Distribution of A
Above Table-V.2.28and Figure
stool (100%) and Excess heat exposure (
Rathamoolam among 20 OP cases. In IP cases 
stool and 50% is due to prolonged sitting and prolonged standing respectively
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-V.2.28 revealed that Excessive Straining at 
75%) have high prevalence
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 V.2.29: Distribution of Degree of Hemorrhoids
         Table-V.2.29: Distribution of Degree of Hemorrhoids
Degree of Hemorrhoids
First Degree 
Second Degree 
Third Degree 
 
         Figure-V.2.29: Distribution of Degree of Hemorrhoids
Above Figure-
20 OP 70% of cases had Fir
hemorrhoids, 5% of cases had third degree hemorrhoids. Out of 20 IP
had First degree hemorrhoids,
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V.2.29&Table-V.2.29 showed that among 40 patients, Out of 
st degree hemorrhoids, 25% of cases had second degree 
 30% of cases had second degree hemorrhoids.
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 V.2.30: Distribution of 
       Table-V.2.30: Distribution of change of symptoms
Symptoms Number 
of cases
Bleeding per 
anus 
40 
Pain around 
anus 
32 
Constipation 40 
Protrusion of 
pilemass 
40 
Mucous 
discharge 
17 
Itchy anus 12 
 
            Figure-V.2.30: Distribution of 
 Above Table-V.2.30 & Figure
improvement in bleeding per anus symptom among 40 patients, 68.75% of cases 
good impovemet in pain around anus symptom among 32 patients, 85% of cases 
good impovemet in constip
good impovemet in protrusion of pil
cases had good impovemet in 
cases had good impovemet in 
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Change of Symptoms 
-V.2.30 revealed that 90% of cases 
ation symptom among 40 patients, 37.5% of cases 
e mass symptom among 40 patients
mucous discharge symptom among 1
itching around anus symptom among 12 patients.
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 V.2.31: Distribution of Hb level
         Table-V.2.31: Distribution of Hb level
Hb level 
(gm/dl) 
6-7.9 
8-9.9 
10-11.9 
12-13.9 
14-15.9 
 
           Figure-V.2.31: Distribution of Hb level
Above Table-V.2.31
20 OP 55% cases had Hb
between the range 12-1
50% cases had Hb level  in between the range 
range 12-13.9. 15% cases had Hb level in between the range of 8
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 & Figure-V.2.31 showed that among 40 patient
 level  in between the range 10-11.9, 
3.9, 10% of cases had in between the range 
10-11.9, 25% cases had in between the 
-9.9.
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 V.2.32: Distribution of Gradation of results
         Table-V.2.32: Distribution of Gradation of results
Gradation of Results
Good 
Moderate 
Mild 
 
           Figure-V.2.32: Distribution of Gradation of results
Above Table-V.2.32 &Figure
patients had good improvement,
improvement. 
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-V.2.32 showed that among 40 patients 73
 23% had moderate improvement and 
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                                              CHAPTER-VI                                        
                                   DISCUSSION 
The Rathamoolam is correlated to Bleeding hemorrhoid in Modern science. 
The types of Moolam, its name, etiology, pathogenesis, clinical features, prognosis 
and treatments etc are being discussed in the review of literature in siddha aspect. The 
modern aspects of Hemorrhoid which include Anatomy, physiology, pathology and 
treatments are also discussed in review chapter. 
         In this trial, 40 cases of Rathamoolam patients who attended the OPD and IPD 
of GSMC, Palayamkottai were selected according to Protocol. The screened and 
selected patients were treated with the Trial medicine Nelli kudineer. Preclinical study 
of NK including Biochemical,Phytochemical,Anti microbial,Pharmacological and 
Toxicity studies also done and proven for its therapeutic uses for Rathamoolam. 
Clinical assessment was carried out before and after the treatment with NK. From my 
trial following findings were observed and discussed. 
VI.1. SIDDHA ASPECT OF NK FOR RATHAMOOLAM 
In Rathamoolam V↑, P↑, Neer↓ 
Line of treatment To normalize ↑V,↑ P, ↓ Neer 
Vatham normalized by  Sweet, Sour, Salt 
Pitham normalized by Sweet, Astringent, Bitter 
Method of preparation Ekamoolikai prayokam 
                                                 GUNAM (PROPERTIES OF NK) 
 
 
Suvai: Taste 
Sweet :    Mann+ Neer Activate 5 sense organs 
 
Sour   :    Mann+ Theyu 
Proper digestion 
Easy defecation 
Nourishes blood vessels 
Astringent: Mann+ Vaayu Constricting effect 
 
Veeriyam: Potency 
 
Cold 
Removes Pitham& Ratham 
↑ Life span 
Give pleasure to mind 
Pirivu:Post absorptive taste Sweet   : Mann+ Neer      Neer bootham maintained 
 
 
Predominent bootham 
 
 
Mann 
Evacuate the thodam within 
the intestine by defecation 
Has qualities of other 
bootham 
Interpretation Gunam of NK normalizes the vitiated Vatham& 
Pitham, Neer bootham attained to its normal level, 
thereby reduced the symptoms of RM. So, Nelli 
Kudineer is effective for the treatment of 
Rathamoolam. 
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                                     VI.2. PRE CLINICAL STUDY OF NK 
Pre clinical study Inference   
(+) Present / (-) absent  
Interpretation 
 
 
 
 
 
 
Biochemical analysis 
Calcium(+) Blood clotting 
Sulphate(+) Increases stool mass 
Chloride(+) Keep the fluid amount inside 
&outside of cells 
Ferrous iron(+) Synthesis of Hb 
Tannic acid(+) Astringent principle, coagulate 
the protein in the skin& protect 
it.Reduces Inflammation, itching, 
mucous discharge around anus. 
Unsaturated compounds(+) Carryout addition reactions, 
More reactive 
Amino acids(+) Ascorbic acid is highly stable; 
stability is attributed to Tannins 
& Poly phenols which retard the 
oxidation of ascorbic acid. 
 
 
 
Phytochemical analysis 
Alkaloids(+) Anti microbial activity 
Phenols(+) Anti oxidant property 
Glycosides(+) Anti viral activity 
Steroids(+) ----------------------------- 
Tannins(+) Astringent, Anti inflammatory, 
Anti infective, Anti oxidant. 
Terpenoids(+) Anti inflammatory. 
Anti microbial assay Anti microbial activity(+)  
Staphylococcus aureus,E.coli 
(ZIC 13,14 mm resply) 
Anti infective  
 
 
 
Pharmacological study 
Anti coagulant action(+) Arrest bleeding  
Laxative action(+) Relieves Constipation  
Analgesic action(+) Relieves Pain around anus 
Anti inflammatory action(+) Subsiding inflammation around 
anus 
Haematinic activity(+) increases Hb level 
Toxicity study Acute toxicity(-) No morbidity& mortality 
Chronic toxicity(-) No evidence of severe Toxicity  
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            VI.3.CLINICAL STUDY OF NK FOR RATHAMOOLAM 
Distribution Prevalence OP IP 
Gender M 50 15 F 50 85 
Age (Yr) 
21-30 30 10 
31-40 20 20 
41-50 35 10 
51-60 15 60 
Religion 
Hindu 60 90 
Muslim 25 0 
Christian 15 10 
Educational 
Status 
Mid. School 10 25 
High School 30 60 
College 35 10 
Occupation 
Housewife 20 30 
Student 15 0 
Labourer 30 45 
Sedentary 35 25 
Socio Economic 
Status 
Upper 20 0 
Middle 50 40 
Lower 30 60 
Marital Status Married 65 95 Unmarried 35 5 
Family H/O  
Hemorrhoids 
Yes 40 30 
No 60 70 
Dietary Habits 
Veg 25 10 
Mixed 75 90 
Timely 20 15 
Untimely 80 85 
Addiction 
Smoking 15 10 
Alcohol 10 5 
Tobacco 15 10 
Coffee 40 45 
Tea 60 55 
Sleep Normal 65 50 Disturbed 30 50 
Previous 
Treatment Yes 30 40 
Nilam 
Kurinchi 5 0 
Marutham 75 65 
Neithal 20 35 
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Kaalam 
Kaar 10 15 
Koothir 15 30 
Munpani 5 20 
Pinpani 5 20 
Ilavenil 35 4 
Mudhuvenil 30 10 
Theki 
VP 40 35 
PV 45 50 
PK 10 5 
Gunam Rajas 100 100 
Kanmenthiriyam Eruvai 100 100 
Aasayangal 
Amarvasayam 60 45 
Pakirvasayam 35 25 
Malavasayam 100 100 
Kosangal Annamayam 60 60 Piranamayam 40 40 
Uyir 
thathukkal 
Vatham 
Pranan 60 45 
Abanan 100 100 
Viyanan 40 30 
Samananan 50 60 
Kirukiran 60 45 
Devathathan 60 45 
Pitham 
Analakam 60 50 
Ranjakam 60 70 
Sathakam 40 35 
Kapam Kilethakam 60 70 
Udal 
thathukkal 
Saaram 60 45 
Senneer 60 70 
Naadi 
V 5 20 
P 10 10 
VP 30 10 
PV 50 60 
PK 5 0 
Envakai  
Thervu 
Sparisam 60 55 
Naa 30 40 
Niram 30 45 
Vizhi 30 50 
Malam 100 100 
Moothiram 35 30 
Neikkuri 
V 5 20 
P 35 20 
K 5 0 
PV 40 60 
KP 5 0 
Challadai 10 0 
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Clinical  
Presentation 
Classical 5 25 
Confirmative 10 20 
Clinical 60 35 
Diagnostic 15 20 
Suggestive 10 0 
Disease 
Criteria 
Bleeding per anus 100 100 
Pain around anus 75 85 
Constipation 100 100 
Prolapse of pilemass 100 100 
Mucous discharge 25 60 
Itching 20 40 
Anemia 65 70 
Duration of 
Illness 
0 M – 6 M 50 20 
6 M – 1 Y 30 50 
1 Y – 2 Y 5 15 
2 Y – 3 Y 15 15 
Aggravating 
Factors 
Excess straining  at stool 100 100 
Prolonged sitting 60 50 
Prolonged standing 40 50 
Excess heat exposure 75 40 
Excess cold exposure  25 15 
Change of dietary habit 55 25 
Psychic disturbances 40 35 
Degree of  
Hemorrhoids 
First 70 70 
Second 25 30 
Third 5 0 
Hb level 
(gm/dl) 
6-7.9 0 5 
8-9.9 10 15 
10-11.9 55 50 
12-13.9 35 25 
Change of 
Symptoms 
Symptoms Good Mod Mild 
Bleeding per anus 90 10 0 
Pain around anus 68.75 25 6.25 
Constipation 85 15 0 
Prolapse of pilemass 37 60 2.5 
Mucous discharge 82.35 11.76 5.88 
Itching 75 16.66 8.33 
Gradation of results 
Good 73 
Moderate 23 
Mild 4 
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VI.4.STATISTICAL ANALYSIS : PRECLINICAL STUDY 
 
 Results are reported as mean + S.E.M. The Statistical Analysis were performed 
using one way analysis of variance(ANOVA). For tests, differences with value of 
P<0.05 (P-value) were considered significant  
Anticoagulant activity Significant reduction in cloting profile P < 0.01 
Laxative action Significant dose dependent increase in faeces output  P<0.01 
Analgesic action Significant analgesic ativity in animal model of pain  P<0.01 
Anti inflammatory action Significant anti inflammatory activity  P<0.01 
Haematinic action Signifiant increase in Hb level P<0.01 
VI.4.STATISTICAL ANALYSIS : CLINICAL STUDY 
 Data were expressed as mean and SD. The significance of the difference between 
before (BT) and after treatement (AT)was tested using Paired 't' test. A probability 
value (P-value) of <0.05 was considered to be statisitically significant. 
Grade BT & AT MEAN STANDARD 
DEVIATION 
t VALUE P VALUE 
Bleeding per 
anus 
BT 1.82 0.874 
 
12.599 
 
< 0.05 AT 0.13 0.335 
Pain around anus BT 1.13 0.791 
 
6.985 
 
< 0.05 AT 0.28 0.452 
Constipation BT 1.48 0.506 
 
15.943 
 
< 0.05 AT 0.15 0.362 
Protrusion of Pile 
mass 
 
BT 1.33 0.526 
 
7.286 
 
< 0.01 AT 0.62 0.540 
Mucous 
Discharge 
BT 0.45 0.552 
 
5.152 
 
< 0.01 AT 0.00 0.000 
Itchy anus BT 0.35 0.580 
 
3.819 
 
< 0.01 
 
AT 0.00 0.000 
Haemoglobin BT 11.183 1.5377 
 
-1.771 
 
< 0.01 AT 11.340 1.2989 
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CHAPTER-VII 
SUMMARY 
The clinical study on Rathamoolam (bleeding Hemorrhoids) consisting of 40 
patients were treated by trail drug Nelli Kudineer 100ml OD morning has been 
evaluated based on pre clinical, clinical and Siddha aspects. High prevalence of 
symptoms in RM were Bleeding per anus, Constipation and Protrusion of pile mass. 
Excessive Straining at stool , Excess heat exposure, prolonged sitting had high 
prevalance in aggravating the Rathamoolam. After treatment there was good 
improvement in symptoms of bleeding per anus and constipation (90% and 85% 
respectively), mucous discharge and itchy anus (82% and 75% 
respectively).Significant increase in Hb level at the 0.01 level (2-tailed). The 
gradation of result was found to be good improvement in 73% cases, moderate 
improvement in 23% cases and mild improvement in 4% cases. None of them 
required any treatment for adverse events. There were no serious adverse and 
unexpected events reported during my clinical trial. The NK proved to be safe 
clinically.  
Preclinical study of Nelli Kudineer revealed the presence of following bio 
chemicals calcium, sulfate, ferrous iron, tannic acid, unsaturated compound and 
amino acid. Presence of Tannic acid in NK has an Astringent Principle, which 
coagulate the protein in skin and protect the tissue by forming a thin layer. It also 
decreases the Mucous and other secretion and there by decreasing inflammation and 
irritation around the anal area and also provide relief from burning and itching but not 
pain. Phytochemical analysis revealed the presence of alkaloids, phenols, glycosides, 
steroids, tannins and terpenoids. Many human physiological activities such as 
stimulation of phagocytic cells, host-mediated tumor activity and anti-infective 
actions assigned to tannins. Phenols act through the mechanism of substance 
deprivation and terpenoids act through the membrane disruption. Pharmacological 
studies of NK proved the styptic (P<0.01), laxative (P<0.01) analgesic (P<0.01), anti-
inflammatory (P<0.01) and hemetenic activity (P<0.01). Acute and chronic toxicity 
study of NK in animals showed no morbidity and mortality. Effect of NK on 
haemetolical parameters of Hb showed significant increase in Hb level (P<0.01). Thus 
above mentioned preclinical study proved that NK is good for the management of 
Rathamoolam. 
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Vatha Pitha thontha deranged Rathamoolam (RM) is normalized by sour, 
astringent, sweet taste of NK. The Cold potency (thatpam) of NK acts on RM by 
eliminating excess pitham. The post absorptive taste (pirivu) of NK is sweet (inippu). 
Vatham and pitham are also normalized by sweet taste. Mann (earth) is predominant 
bootha in NK which evacuate the thodam within the intestine by defection there by it 
improved the function of abanavaayu, which regulate the bowel habits and lead to 
normal functioning of udal thathus. Gunam of NK normalizes the vitiated 
Vatham& Pitham, Neer bootham attained to its normal level, thereby reduced 
the symptoms of RM. So,the trial summerised that Nelli Kudineer is effective for 
the treatment of Rathamoolam. 
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CHAPTER-VIII 
CONCLUSION 
My thesis prospective open labelled phase-II non randomized clinical study of 
Nelli Kudineer (NK) for Rathamoolam (RM) in modern science bleeding hemorrhoids 
concluded the clinical and therapeutic efficacy of NK for RM by showing 
improvement in grades of symptoms.  No adverse events were reported during the 
clinical study, the trial drug appears to be safe. The pre clinical studies including bio 
chemical, Phytochemical, anti microbial and pharmacological evaluation revealed the 
presence of various bio chemicals, phytochemicals and showed good styptic, laxative, 
anti inflammatory and haemetenic action.The acute and chronic toxicity study showed 
the good safety profile of NK. The panchabootham, taste, potency and post absorptive 
taste (pirivu) of NK was found to correct the deranged humors there by regulizing the 
udal thathus and proved the effective management of RM.  
  Bio statistical analysis of pharmacological study showed the significant styptic 
action (P value<0.01), laxative action (P value<0.01), analgesic action (P value<0.01), 
anti inflammatory (P value<0.01), haemetenic action (P value<0.01). NK showed 
significant degrees in plasma cholesterol, TG, LDL (P value<0.05), significant 
increase in HDL cholesterol (P value<0.05). AST, ALT, ALP levels were normal in 
NK treated animals (P value<0.05). NK showed the significant increase in Hb level (P 
value<0.01).  
  The clinical manifestations (bleeding, pain, constipation, protrusion of 
pilemass) of RM before treatment and after treatment is statistically significant 
(P<0.05). Other manifestations (Mucous discharge, itching) also statistically 
significant   (P<0.01). The clinical studies in both OP & IP were motivating and gave 
hope in the management of RM. The gradation of result was found to be good 
improvement in 73% cases, moderate improvement in 23% cases and mild 
improvement in 4% cases.  
  This is only a preliminary study and by understanding limitations from this 
study,  elaborate study will be undertaken to assess the further more effect of NK. 
Siddha way of approach is certainly the best treatment of RM in all aspects, because 
of encouraging results clinically and pre clinically, it is concluded that RM is 
manageable with NK.  
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ANNEXURE-V.I 
DISEASE CRITERIA  
 
GOVT. SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI - 2 
DEPARTMENT OF POTHUMARUTHUVAM 
A Prospective open labelled Phase II Non - Randomized Clinical Study of  
NELLI KUDINEER for RATHAMOOLAM (Bleeding Hemorrhoids) 
Name      : ……………………………………………………… 
Age/ Gender    :……………………………………………………… 
DISEASE CRITERIA FOR ASSESSMENTRaakhi Mehra,et al,Ayu.2011) 
Sl.No Parameter Grade 0 
(G0) 
Grade 1 (G1) Grade2 (G2) Grade3 (G3)  
1 Bleeding Per Anus Nil Mild 
(Occasionally) 
Moderate 
(Weekly/Monthly) 
Severe 
(On each 
defaecation) 
2 Pain around anus Nil Mild 
(Lasts for < 1 Hr 
Moderate 
(Last for 1-2hr) 
Severe 
(Last for>2hrs) 
3 Constipation 
(Bristol stool scale) 
Nil Mild 
(Type 2 ) 
(on alternate 
days) 
Moderate 
(Type 2) 
( 2-3 days) 
Severe 
(Type I) 
(>3 days) 
4 Protrusion of pile mass Nil Protrude into 
analcanal,no 
prolapse. 
Prolapse out of  
anal 
canal,spontaneous 
reduction 
Prolapse out of 
anal 
canal,manual 
reduction. 
5 Mucous discharge. Nil Mild Moderate Severe 
6 Itchy anus Nil Mild Moderate Severe 
7 Anemia [Hb (g/dl)] Nil Mild 
Men : 11-12.9 
Women :11-11.9 
Moderate 
(8-10.9) 
Severe 
(<8) 
 
  
  
ANNEXURE-V. 2 
CASE SHEET REPORT OF OP & IP  
CASE SHEET OF 20 PATIENTS TREATED IN OP FOR RATHAMOOLAM 
Sl 
no 
OP no Name 
Age/ 
gender 
Occupation 
Duration 
of illness 
Date of 
onset 
treatment 
Date of 
terminati
on of 
treatment 
Total 
days 
1 31681 Sreenivasan 40/M Cook 6 months 05.04.18 04.05.18 30 
2 34770 Sabeena 32/F House wife 1 year 16.04.18 15.05.18 30 
3 38621 Epzi 42/F Office work 2 months 30.04.18 30.05.18 30 
4 42498 Prema 60/F House wife 5 months 14.05.18 13.06.18 30 
5 45205 Swarnapadma 45/F House wife 2 years 24.05.18 23.06.18 30 
6 47092 Kalaivani 46/F House wife 2 years 31.05.18 30.06.18 30 
7 50077 Inbarakavan 20/M Student 1 year 12.06.18 11.07.18 30 
8 50288 Kannan 39/M Driver 1 year 13.06.18 12.07.18 30 
9 52145 Risvana 23/F Student 1 month 20.06.18 19.07.18 30 
10 53878 Habeeba 20/F Student 1 year 26.06.18 25.07.18 30 
11 57212 Murukan 28/M Carpenter 1 year 09.07.18 08.08.18 30 
12 60525 Mumthaz 43/F Tailor 3 months 20.07.18 19.08.18 30 
13 61648 Sudalaimuthu 47/M Cook 6 months 24.07.18 23.08.18 30 
14 63912 Sundar 45/M Marketing 2 months 01.08.18 31.08.18 30 
15 67485 Sanmugam 49/M Salesman 2 months 14.08.18 13.09.18 31 
16 81122 Manikandan 25/M Police 1 year 01.10.18 31.10.18 30 
17 85158 Jayalakshmi 60/F Teacher 1 year 16.10.18 14.11.18 30 
18 97696 Suresh 40/M Supervisor 1 month 26.11.18 25.12.18 30 
19 10193 Stalin 60/M Supervisor 3 year 03.12.18 01.01.19 30 
20 533 Noorjahan 22/F IT 6 months 02.01.19 31.01.19 30 
  
 
CASE SHEET OF 20 PATIENTS TREATED IN IP FOR RATHAMOOLAM 
 
Sl 
no 
IP 
no 
Name Age/ 
Gender 
Occupation Duratio
n of  
Illness 
Date of 
admission 
Date of 
termination 
Total 
no of 
days 
1 1360 Krishnaveni 30/F Tailor 2 years 22.05.18 21.06.18 30 
2 1783 Kuruvammal 37/F Housewife 1 month 13.07.18 12.08.18 30 
3 1918 Anthoniyammal 31/F Housewife 6 
months 
27.07.18 26.08.18 30 
4 2141 Madathi 60/F House wife 7 
months 
22.08.18 21.09.18 30 
5 2216 Esumani 60/F House wife 2 
months 
29.08.18 28.09.18 30 
6 2394 Nallammal 53/F Tailor 1 year 22.10.18 21.11.18 30 
7 2715 Mariyammal 50/F Cook 3 year 08.11.18 07.12.18 30 
8 2804 Ravi 22/F Field work 1 month 16.11.18 15.12.18 30 
9 2938 Lalithasenbakam 60/F House wife 1 year 01.12.18 01.01.19 30 
10 2987 Manonmani 59/F Cook 8 
months 
07.12.18 06.01.19 30 
11 3016 Arumukam 60/F Cook 1 year 10.12.18 09.01.19 30 
12 3047 Pechiyammal 55/F Cook 8 
months 
11.12.18 10.01.19 30 
13 96 Sivaraman 43/M Driver 1 year 20.01.19 19.02.19 30 
14 267 Muthu 53/F Cook 1 
1/2years 
06.02.19 07.03.19 30 
15 296 Subbulakshmi 58/F Cook 2 years 08.02.19 11.03.19 30 
16 312 Makavathi 39/F Tailor 1 year 09.02.19 11.03.19 30 
17 416 Mallika 50/F Tailor 8 
months 
25.02.19 26.03.19 30 
18 505 Selvi 52/F Cook 3 years 27.02.19 28.03.19 30 
19 606 Pandarathi 60/F House wife 1 year 08.03.19 07.04.19 30 
20 650 Chellammal 60/F House wife 2 years 13.03.19 12.04.19 30 
 
  
BLOOD INVESTIGATION CHART FOR OUT-PATIENT 
SI 
No. 
OP 
NO. 
 BEFORE 
TREATMENT 
 AFTER TREATMENT 
Hb TC DC ESR Hb TC DC ESR 
P L E   P      L   E 
1 31681 11.8 
7000 60 38 02 
8 11.8 
8100 62 28 10 
8 
2 34770 10.1 
7300 65 32 03 
4 10.2 
7000 60 36 04 
4 
3 38621 11.5 
7400 52 45 03 
14 11.8 
7500 68 28 04 
14 
4 42498 10.9 
8000 70 26 04 
4 11 
8100 70 28 02 
4 
5 45205 10.5 
7200 62 36 02 
4 10.6 
7600 60 36 04 
4 
6 47092 11 
8300 62 32 06 
16 11 
8000 62 33 05 
16 
7 50077 13.5 
7500 62 35 03 
26 13.5 
5500 63 34 03 
14 
8 50288 12.5 
8700 64 32 04 
26 12.5 
8400 64 33 03 
12 
9 52145 10.4 
8200 62 34 04 
24 10.4 
7000 62 34 04 
20 
10 53878 11.1 
7000 60 36 04 
12 11.1 
6400 66 26 08 
8 
11 57212 12.1 
7300 64 29 07 
32 12.1 
7500 62 36 02 
28 
12 60525 11 
8500 65 29 06 
18 11.1 
8000 64 30 06 
18 
13 61648 12.5 
8400 64 32 04 
24 12.5 
6400 65 32 03 
24 
14 63912 12.6 
6400 56 40 04 
14 12.6 
6800 58 40 02 
14 
15 67485 8.3 
7000 65 31 04 
64 9.6 
7800 66 30 04 
60 
16 81122 11.9 
8800 59 37 04 
32 11.9 
9000 60 38 02 
30 
17 85158 9.1 
7500 68 30 02 
14 11 
8400 68 30 02 
12 
18 97696 13 
8000 52 45 03 
16 13 
7500 68 28 04 
18 
19 10193 12 
6200 60 36 04 
20 12 
6100 64 30 06 
20 
20 533 10.6 
4200 64 34 02 
4 10.8 
4500 64 31 03 
4 
 
  
  
BLOOD INVESTIGATION CHART FOR IN-PATIENT 
SI 
No. 
IP NO. BEFORE TREATMENT AFTER TREATMENT 
Hb TC          DC ESR Hb TC       DC  ESR 
P L E   P      L   E 
1 1360 9.2 8000 66 28 06 25 9.3 6500 60 34 06 20 
2 1783 8.4 7800 65 31 04 20 8.6 7500 66 30 04 30 
3 1918 11.5 9800 70 26 04 18 11.7 8900 68 28 04 15 
4 2141 12.5 9000 58 38 04 15 12.5 7200 65 33 02 10 
5 2216 11 8000 62 36 02 8 11.3 8000 62 36 02 8 
6 2394 9.4 7100 58 37 05 50 9.5 7000 60 34 06 35 
7 2715 11 8200 60 35 05 35 11 8000 62 36 02 20 
8 2804 13 7100 62 32 06 10 13 8000 58 38 04 10 
9 2938 11.6 8600 60 24 16 20 11.7 8100 60 36 04 15 
10 2987 11.9 8800 64 30 06 5 10 7800 64 32 04 5 
11 3016 11.5 6800 58 38 04 30 11.5 7000 60 38 02 30 
12 3047 12.1 7000 65 32 03 10 12.1 6400 60 36 04 12 
13 96 14 8000 64 30 06 40 14 8500 66 31 03 40 
14 267 12.1 9100 54 44 02 20 12.1 9500 60 33 07 15 
15 296 10.3 8100 64 32 04 45 11.5 8000 66 28 06 40 
16 312 13 8100 60 38 02 70 13 8400 62 28 10 50 
17 416 10.4 8100 60 35 05 10 10.5 8100 60 38 02 10 
18 505 11 6500 61 35 04 20 11 6500 60 36 04 25 
19 606 10.8 7500 62 36 02 5 11 7500 64 32 04 10 
20 650 6.2 
9600 66 31 03 
30 7.8 7000 62 38 00 20 
 
  
  
URINE INVESTIGATION CHART OF OUT-PATIENT 
SL 
NO 
OP NO BEFORE TREATMENT AFTER TREATMENT 
Albumin Sugar Deposits Albumin Sugar Deposits 
1 31681 Nil Nil Nil Nil Nil Nil 
2 34770 Nil Nil Nil Nil Nil Nil 
3 38621 Nil Nil Nil Nil Nil Nil 
4 42498 Nil + Few ept 
cells 
Nil Nil Nil 
5 45205 Nil Nil Nil Nil Nil Nil 
6 47092 Nil Nil Nil Nil Nil Nil 
7 50077 Nil Nil Nil Nil Nil Nil 
8 50288 Nil Nil Nil Nil Nil Nil 
9 52145 Nil Nil  Nil Nil Nil Nil 
10 53878 Nil Nil Nil Nil Nil Nil 
11 57212 Nil Nil Bact+ Nil Nil Nil 
12 60525 Nil Nil Nil Nil Nil Nil 
13 61648 Nil Nil Nil Nil Nil Nil 
14 63912 Nil Nil Nil Nil Nil Nil 
15 67485 Nil Nil Nil Nil Nil Nil 
16 81122 Nil Nil Nil Nil Nil Nil 
17 85158 Nil Nil Nil Nil Nil Nil 
18 97696 Nil Nil Nil Nil Nil Nil 
19 10193 Nil Nil Nil Nil Nil Nil 
20 533 Nil Nil Nil Nil Nil Nil 
 
  
  
URINE INVESTIGATION CHART OF IN-PATIENT 
SL 
NO 
IP NO BEFORE TREATMENT AFTER TREATMENT 
Albumin Sugar Albumin Sugar Albumin Sugar 
1 1360 NIL Nil Nil Nil Nil Nil 
2 1783 + Nil Nil Nil Nil Nil 
3 1918 Nil Nil Nil Nil Nil Nil 
4 2141 Nil Nil ET cell+ Nil Nil Nil 
5 2216 Nil + Nil Nil Nil Nil 
6 2394 Nil Nil Nil Nil Nil Nil 
7 2715 Nil Nil Nil Nil Nil Nil 
8 2804 Nil Nil Nil Nil Nil Nil 
9 2938 Nil Nil Nil Nil Nil Nil 
10 2987 Nil + Nil Nil Nil Nil 
11 3016 Nil Nil Nil Nil Nil Nil 
12 3047 Nil Nil Pus 
cells+ 
Nil Nil Nil 
13 96 Nil Nil Nil Nil Nil Nil 
14 267 Nil Nil Nil Nil Nil Nil 
15 296 + Nil Nil Nil Nil Nil 
16 312 Nil Nil Nil Nil Nil Nil 
17 416 Nil Nil Nil Nil Nil Nil 
18 505 Nil Nil Nil Nil Nil Nil 
19 606 Nil + Nil Nil Nil Nil 
20 650 Nil Nil Nil Nil Nil Nil 
 
  
  
ANNEXURE-VI 
PROCTOSCOPIC EXAMINATION 
 
 
 
 
 
 
Proctoscopic view: IP no- 650 (AT) 
Proctoscopic view: IP no- 650 (BT) 
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